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Abstract 
The introduction of screening mammography in Australia has been associated with an 
increase in the incidence of early-stage breast cancer. Concern is growing about the 
problems caused when women are diagnosed with breast cancer and undergo treatments 
that do not benefit them because their cancer would not progress, or would progress, but 
would not become symptomatic within the remaining lifetime of the patient. This is 
known as overdiagnosis. Screening mammography aims to decrease breast cancer 
morbidity and mortality by advancing in time the diagnosis and thereby increasing the 
chance of successful treatment. But overdiagnosis and the consequent overtreatment can 
cause serious lifelong harm and are therefore considered the major downsides of breast 
screening. Mounting evidence of the extent of overdiagnosis has led to the recognition 
that the benefits and harms of breast screening are finely balanced, and women need to 
know the magnitude of the trade-offs. The extent of overdiagnosis due to breast screening 
is contested, with published estimates ranging from 1% to 57%. There is a critical need for 
research investigating the harm to benefit ratio in Australia and quantification of the 
effects of screening mammography on the incidence of stage-specific breast cancer and 
overdiagnosis. 
Individual women require information about the impact of regularly attending screening 
mammography on breast cancer mortality and overdiagnosis to make informed decisions. 
A challenge to estimating this in a randomised controlled trial is nonadherence to the trial 
protocol. Previous systematic reviews have provided estimates of the effect of receiving an 
invitation to screening on the risk of dying due to breast cancer. Chapter 2 presents a meta-
analysis of the screening mammography trials using a simple adjustment that estimates 
the probability of a reduction in breast cancer mortality and risk of overdiagnosis due to 
the effect of receiving screening by regularly participating in a breast screening program. 
Adjustment for nonadherence increased the size of the size of the effect by up to 50%. The 
prevented fraction of breast cancer mortality at 13-year follow-up increased from 0.22 to 
0.30 with deattenuation. The percentage risk of overdiagnosis during the screening period 
in women invited to screening increased from 19.0% to 29.7%. 
From 2013 through 2017, the Australian national breast cancer screening programme 
gradually invited women aged 70 to 74 years to attend screening, following a policy 
decision to extend invitations to older women. Yet no formal evaluation of the effects of 
the change in policy on outcomes for women was undertaken. Building on my meta-
analysis, in Chapter 3 I used a Markov model and applied the breast cancer mortality 
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reduction and overdiagnosis estimates reported in Chapter 2 to Australian breast cancer 
incidence and mortality data to estimate the benefits and harms of the new package of 
biennial screening from age 50 to 74 compared with the previous programme of screening 
from age 50 to 69. I found that the extra five years of screening results in approximately 
seven more overdiagnosed cancers to avert one more breast cancer death. Thus extending 
screening mammography in Australia to older women results in a less favourable harm to 
benefit ratio than stopping at age 69. 
To identify temporal trends in stage-specific breast cancer in Australia, I used an 
observational study design to analyse data on women who received a diagnosis of breast 
cancer from 1972 to 2012 as recorded in the New South Wales Cancer Registry (Chapter 4). 
I explored trends in stage-specific incidence before screening and compared them to 
periods after screening began. I found that screening was not associated with lower 
incidence of late-stage breast cancer at diagnosis and incidence for all stages remained 
higher than prescreening levels. In women aged 50 to 69 years, the incidence of carcinoma 
in situ, localised and regional breast cancer has more than doubled compared to the 
prescreening era. 
The data presented in Chapter 4 indicate that excess detection of breast cancer is a 
problem in New South Wales. Thus I designed an ecological study to quantify 
overdiagnosis. I estimated the background trend of increasing incidence using two 
approaches, the first based on the prescreening trend in women of screening age (50 years 
and older), and the second based on the contemporary trend in women too young to be 
screened (40 to 44 years of age). From these trends, I estimated the expected age-
standardised incidence of breast cancer, by stage at diagnosis, in the absence of screening, 
for women aged 50 years and over in the years since the national screening mammography 
program, BreastScreen, was introduced (1988 to 2012). I then calculated the difference in 
observed and expected incidence rates to determine the excess incidence of early-stage 
breast cancer and reduction in the incidence of late-stage disease. I found that screening 
mammography has resulted in overdiagnosis of early-stage and regional breast cancer. I 
estimate that around six additional cases of early and regional breast cancer are detected 
for every distant metastatic breast cancer prevented. 
Due to the substantial increase in detection of carcinoma in situ of the breast observed in 
Chapter 4, I explored sub-types and causes of this. Chapter 6 presents a descriptive analysis 
of temporal trends in the incidence of ductal carcinoma in situ (DCIS) and lobular 
carcinoma in situ (LCIS) in women who received a diagnosis from 1972 to 2012, recorded 
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in the NSW Cancer Registry. Carcinoma in situ as a proportion of all breast cancer 
increased dramatically, and incidence of DCIS across all ages rose from 0.15 per 100,000 
during 1972 to 1983 to 16.81 per 100,000 over 2006 to 2012, with the greatest increase seen 
among women in the target age group for screening (50 to 69 years). DCIS incidence has 
not stabilized despite screening being well established for over 20 years, and participation 
rates in the target age range remaining stable. 
Our observational estimate of overdiagnosis from Chapter 5 is different to those from 
meta-analyses of randomised controlled trials of screening mammography and some other 
observational studies. Thus the final paper in this thesis presents a Cochrane Protocol on 
Overdiagnosis due to screening mammography for women aged 40 years and older 
(Chapter 7). We present methodology to identify and evaluate all primary epidemiological 
studies that have quantified overdiagnosis resulting from screening mammography and 
provide estimates of its frequency (including randomised and observational studies). An 
approach to assessing the risk of bias due to lead time is also discussed. 
Trying to quantify the benefits and harms of screening mammography and present them 
to women using natural frequencies should better enable informed choice, and is 
consistent with the international shift towards promoting and supporting shared decision 
making for screening. This thesis provides valuable new evidence about the trade-offs of 
screening mammography in Australia. The finding that risk of harm is greater than the 
chance of benefit is consistent with international studies of breast screening and 
demonstrates the importance of continuing this work to better quantify overdiagnosis for 
women, clinicians, and policymakers. 
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Chapter 1. Introduction 
Background 
Breast cancer is the most common cancer in Australian women and internationally1 with 
incidence rising dramatically over the past 40 years. Since 1983, the risk of a woman being 
diagnosed with breast cancer before age 75 has increased from one in 16 to one in 10.2 
Changes in lifestyle-related risk factors have contributed to increasing incidence, 
including changes in reproductive factors, post-menopausal obesity, and use of hormone 
therapy.3 It has become increasingly clear, however, that the introduction of population 
screening mammography for breast cancer has been the primary contributory factor. 
Screening mammography for breast cancer 
Screening mammography involves periodically performing x-rays of the breast in 
asymptomatic women to identify early imaging signs of breast cancer. Detecting cancer 
earlier in the natural history of the disease should reduce breast cancer mortality and 
morbidity by advancing in time the diagnosis and thereby increasing the chance of 
successful treatment. 
The introduction of population screening in Australia 
Screening mammography in Australia was introduced following the publication of initial 
trial results that screening mammography reduced breast cancer mortality.4, 5 The Forrest 
report in 1986 concluded that the introduction of screening had the potential to reduce 
deaths due to breast cancer and led to national programs in the UK and Australia.6 From 
1988 the Australian government began pilot screening mammography services to evaluate 
the feasibility and cost-effectiveness of providing a national program to all women aged 
40 years and older in Australia.7 Following the pilot scheme, an evaluation report 
recommended that a national screening program be implemented.8 In 1991 the 
government began targeting women aged 50 to 69 years, and by 1996 it reached full 
geographical reach. 
BreastScreen Australia provides free biennial screening to women aged 40 years and older 
at average risk of breast cancer.9 The program is similar to population-based screening 
programs offered in other countries.10 While coordination of BreastScreen is at a national 
level, the Australian state and territory governments have responsibility for the 
implementation and strategies at a local level. BreastScreen Australia uses two-view 
mammography (craniocaudal and mediolateral) with independent reading by two trained 
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screen-readers, at least one of whom is a radiologist.11 Women in the target ages of 50 to 
69 years are sent letters of invitation, with follow-up letters sent to those who do not 
respond. BreastScreen Australia has used additional methods to recruit eligible women 
within and outside of the target age range to screening, including mass marketing 
campaigns (including television, radio, and print media), social media and GP reminders.7 
Early detection now forms a cornerstone of Australia's cancer policy, with the Australian 
Government making cancer and cancer control a National Health Priority Area. In 2014, 
the Australian Government spent over $235 million on BreastScreen Australia which was 
accessed by almost 1.5 million women aged 50 to 69 years.9 Breast cancer screening is 
clearly well established, and currently expanding. As part of the 2013-2014 Federal Budget, 
the Australian Government committed a further $55.7 million to extend BreastScreen 
Australia’s target age range from 50 to 69 years to 50 to 74 years of age over four years.9 
The evidence for benefit from screening mammography 
Beginning with the Health Insurance Plan (HIP) trial in New York in 1963, the effect of 
screening mammography on breast cancer has been evaluated in eleven randomised trials 
involving more than 650,000 women in Europe and North America.4, 5, 12-17 Meta-analyses 
of these trials report a reduction in breast cancer mortality of between 15% to 20% for 
women invited to screening,18-23 but no effect on all-cause mortality. The effect in women 
who receive screening has been estimated to be closer to 37% when an intention to screen 
estimates are adjusted for attendance in these trials.24 Since the trials were conducted, 
breast cancer treatment has advanced significantly, resulting in reduced mortality among 
women with both early- and regional disease. Thus, screening may not be as beneficial 
today as it was when the trials were performed. Regardless, estimates of the absolute 
benefit of screening are small, ranging from one breast cancer death averted for every 100 
to 2000 women invited to screening.18-20, 23, 25-27 More contemporary estimates of mortality 
reduction are available from observational studies.28 These results demonstrate a larger 
effect than the trials but are prone to important biases such as lead time, length time and 
selection bias. 
The evidence for harm from screening mammography 
Like most health interventions, screening mammography for breast cancer involves risk 
of harm. The most frequent harm is false positive results: when a breast abnormality is 
detected by screening mammography but with further investigation, no cancer is found. 
False positives cause pain and scarring, anxiety and inconvenience due to additional 
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testing. Another less frequent harm is false negatives, which can create a false sense of 
security and potentially delay a cancer diagnosis.29 But arguably the most important and 
severe harm is overdiagnosis. 
Increasing incidence of breast cancer 
From 1982 until 2013, the age-standardised incidence of invasive breast cancer in 
Australian women has increased from 81 per 100,000 to 123 per 100,000.2 A pattern of 
increasing incidence of early-stage breast cancer that corresponds temporally with 
screening mammography has been observed in Australia.30, 31 The effect of this increase on 
late-stage disease in Australia is largely unknown. 
Overdiagnosis 
An important and growing concern in modern medicine is overdiagnosis – which may be 
defined in general, as when a health-related problem is correctly identified and labelled 
(an intervention may also be offered) but this does not benefit the person diagnosed.32 
Overdiagnosis occurs through various mechanisms such as testing asymptomatic 
populations, increasingly sensitive tests, incidental findings on imaging, and widening 
disease definitions.33 The key drivers are various and complex, including the health system, 
industry and technology, healthcare professionals, patients and the public, and the culture 
of medicine and society more broadly.34 
Welch (2010) defined overdiagnosis as a diagnosed cancer that would otherwise not go on 
to cause symptoms or death, but which fulfils the pathological criteria for cancer.35 For 
this thesis, I define overdiagnosis in the same way as a preclinical tumour that would not 
have become symptomatic but fulfils the pathological criteria for cancer. Such cancers, 
when diagnosed by breast screening, do not benefit women because either they would not 
progress (dormant or indolent cancers), or they would progress, but would not become 
symptomatic within the remaining lifetime of the patient (and are therefore dependent on 
competing mortality as well as on the biologic potential of the cancer). 
The presence and effects of overdiagnosis are intangible, evident in population statistics 
rather than observable clinical outcomes because treatment after detection is almost 
universal and it is not possible to observe the counterfactual scenario. In practice, almost 
all patients undergo treatment which carries the risk of iatrogenic harms, as well as the 
psycho-social harms of labelling women with a breast cancer diagnosis. 
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The concept of overdiagnosis in relation to cancer screening is not new.36, 37 Large increases 
in the incidence of early-stage breast cancer were observed in the USA as far back as 1969, 
coinciding with the introduction of screening mammography,36 and later in Europe, 
Canada, and Australia.31, 38 Indeed, the UK Forrest Report acknowledged the existence of 
overdiagnosis.6 It is only with recent mounting evidence of the scale of the issue that 
overdiagnosis has become a mainstream idea. In 2011 the Independent UK Panel on Breast 
Cancer Screening was formed on the back of controversy and polarising debate around the 
trade-offs of screening mammography, including the growing evidence of overdiagnosis 
In 2012, The UK Panel released a report concluding that screening reduced breast cancer 
mortality but that it was associated with substantial overdiagnosis,20 making it impossible 
for screening services in the UK and Australia to continue to deny overdiagnosis as an 
important harm of breast screening. In that report, the authors emphasised the 
uncertainty surrounding the precise estimate of overdiagnosis due to the few trials and 
increasing sensitivity of current technology. This uncertainty is further confounded by a 
trend towards lower radiologic and pathologic diagnostic thresholds. 
Several meta-analyses and many more observational studies have been published since the 
Independent UK Panel report, yet there is still no consensus on the risk of overdiagnosis 
due to screening mammography. The issue remains complicated by a lack of agreement 
on the most appropriate methodology to estimate overdiagnosis and ethical, cultural, 
political and scientific disagreements which influence the generation and interpretation 
of the evidence. 
Importance of quantifying overdiagnosis 
Both the concept and amount of overdiagnosis are important to women,39 and the estimate 
can be critical for policymakers. When evaluating screening programs, decisions are based 
on the evidence of benefits and harms, but heavily influenced by ethical and 
epistemological values.40 A change in the frequency of overdiagnosis can shift the benefits 
to harm trade-off. Therefore, an accurate estimate of overdiagnosis is important for both 
individual and public health decision-making. While a meta-analysis of the trials estimates 
the risk of overdiagnosis in women invited to screening to be 19%, no trials have been 
conducted in Australia. Researchers have used observational studies to quantify 
overdiagnosis resulting from screening mammography in Australia, but these estimates 
vary widely and are difficult to compare to international results due to novel methods used 
in existing Australian studies.3, 41, 42 
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Challenges in quantifying overdiagnosis 
Many researchers have attempted to calculate overdiagnosis, yet estimates remain highly 
variable. Discrepancies persist about how best to quantify overdiagnosis and the validity 
of different methodological approaches. 
Study design 
Various study designs have been used to estimate overdiagnosis, including randomised 
controlled trials, observational studies (cohort, ecological and nested case-control 
studies), and disease progression modelling studies. While each approach has strengths 
and limitations, a difficulty when evaluating contemporary screening programs is finding 
an unscreened reference population with the same risk of breast cancer as the invited 
population. This problem is best solved by randomised controlled trials where screening 
is performed for a period and then stopped, but follow-up continues. Only three of the 11 
screening mammography trials did not invite the intervention or control groups to screen 
at the end of the intervention period (often referred to as a “stop screen trial”) and allowed 
for long-term follow-up: Malmö I (women aged 55 to 69 years),43 and the two parts of the 
Canadian National Breast Screen Study.13, 14 Randomised controlled trials, however, can be 
difficult to conduct due to funding, recruitment and sample size, adherence, and long-
term follow-up. Further, they may not reflect real-world clinical practice. While more 
contemporary estimates of breast cancer overdiagnosis from observational studies are 
available, figures vary widely between studies, ranging from 1% to 57%.44, 45 A systematic 
review by Carter (2015), however, found well-designed and conducted observational 
studies best for monitoring overdiagnosis within contemporary cancer screening 
programs due to their better applicability.46 The validity of modelling studies that attempt 
to estimate overdiagnosis is questionable, given they simulate the natural history of 
screen-detected breast cancer, a phenomenon that cannot be observed. Thus accurately 
measuring overdiagnosis due to screening mammography is an important concern for 
epidemiology and public health. 
Methods 
The main disagreements in methods surround adjustment for lead time. Adequately 
adjusting for lead time is complex but essential in screening studies that estimate 
overdiagnosis because lead time will cause a temporary increase in cancer incidence that 
will subside once screening stops.47 As such, studies that estimate overdiagnosis without 
allowing for lead time will overestimate overdiagnosis.48, 49 There are three main 
6 
approaches to adjust for lead time: the excess incidence approach (which can be 
categorised into the cumulative incidence approach and early vs late-stage cancer 
approach); the lead time approach (which can be divided into the mean lead time 
approach, lead time distribution approach, and natural history modelling);50 and the 
screen difference estimate.51 The excess incidence approach for a “stop screen trial” is best 
equipped to allow for lead time. Modelling estimates are the most prone to bias, with small 
model misspecifications leading to substantial error. 
Concerning methods used to obtain unscreened reference populations, the choice of 
reference group can be classified as: (a) control group of a randomized controlled trial, (b) 
contemporaneous control groups such as non-attenders, control region, or uninvited 
groups in contemporaneous observational studies, (c) historical control groups such as 
extrapolation of a prescreening trend, and (d) estimation using natural history modelling. 
Again, well-conducted randomised controlled trials will provide the best reference 
population as all known and unknown confounders will be equally distributed between 
groups. Modelled estimates of expected incidence in unscreened references populations 
are based on assumptions and extrapolation and thus involve much uncertainty. 
Summary of gaps in existing knowledge 
As outlined above, we need to accurately estimate the outcomes of screening 
mammography in Australia and present the benefits and harms as natural frequencies.52 
This improves risk perception for individuals, clinicians, and policymakers and leads to 
informed decision making.53 Firstly, we need to adjust trial estimates of the effect of being 
invited to screening for nonadherence occurring after randomisation to obtain the 
magnitude of the ‘real’ effects of attending screening. Several methods exist to validly 
estimate the de-attenuated effect of receiving screening on mortality benefit from 
randomized trials,24, 54-56 but no methods or estimates exist for overdiagnosis. Secondly, we 
need to apply these estimates to Australian data to estimate the effects of extending 
screening to older women under the revised BreastScreen Australia program. This 
estimation did not occur before the change in screening policy and thus the benefit-harm 
trade-off of this decision is largely unknown. 
The other key questions concern the effect of screening mammography on the incidence 
of stage-specific breast cancer in Australia over the last 40 years, and the extent of 
overdiagnosis attributable to screening. My thesis has sought to generate evidence to help 
address these important gaps in knowledge. Further, systematic analysis of Australian data 
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and comparison with international studies may reveal important features that can explain 
the observed variation in estimates between these settings. 
Aims, scope, and structure of thesis 
My thesis is concerned with quantifying the benefits and harms of screening 
mammography in the Australian setting. I aim to explore the temporal impact of 
BreastScreen Australia on stage-specific breast cancer incidence, breast cancer mortality 
and overdiagnosis, and to quantify outcomes to assist women and clinicians in shared 
decision making, as well as policymakers when developing information materials about 
cancer screening for individuals. 
The structure of the thesis includes a series of papers written by me as lead author and 
published in peer-reviewed journals between 2015 and 2017, as well as a protocol that is 
currently awaiting final methodological approval before publication in the Cochrane 
Database of Systematic Reviews, and one unpublished chapter, which quantifies 
overdiagnosis. The present chapter, Chapter 1, has introduced the context and background 
to my research. Chapter 2 summarises the existing trial evidence for the benefits and 
harms of screening mammography and adjusts pooled estimates for nonadherence to 
evaluate the effect of attending screening. Chapter 3 presents outcomes of the impact of 
extending screening mammography in Australia to older women. Chapter 4 describes 
temporal trends in the incidence of stage-specific breast cancer in New South Wales, 
Australia. Chapter 5 reports an ecological study of breast cancer stage and overdiagnosis. 
Due to the substantial increase in detection of carcinoma in situ of the breast observed in 
Australia and the trend for more aggressive treatment,57 it is important to explore sub-
types and causes. Thus, Chapter 6 describes temporal trends in the incidence of ductal and 
lobular carcinoma in situ of the breast in New South Wales. Chapter 7 presents the 
Cochrane Protocol on Overdiagnosis due to screening mammography for women aged 40 
years and older. Finally, Chapter 8 concludes by summarising and discussing the findings 
and implications of my research. 
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Chapter 2. Meta-analysis of breast cancer mortality benefit 
and overdiagnosis adjusted for adherence: improving 
information on the effects of attending screening 
mammography 
This is a meta-analysis of the screening mammography trials using an adjustment that 
estimates the probability of a reduction in breast cancer mortality and risk of 
overdiagnosis due to the effect of receiving screening by regularly participating in a breast 
screening program. The aim was to develop estimates of the impact of receiving screening 
mammography on breast cancer mortality and overdiagnosis to be used when producing 
information for women about the impact of regularly attending screening mammography. 
It was published in the British Journal of Cancer. 
Chapter 2 is published as: 
Jacklyn G, Glasziou P, Macaskill P, Barratt A. Meta-analysis of breast cancer mortality 
benefit and overdiagnosis adjusted for adherence: improving information on the effects of 
attending screening mammography. British Journal of Cancer 2016;114(11):1269-76. 
Available at: http://dx.doi.org/10.1038/bjc.2016.90 
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Chapter 3. Impact of extending screening mammography 
to older women: information to support informed choices 
This paper reports a Markov model that estimates the benefits and harms of a new package 
of biennial screening mammography in Australia from age 50 to 74 compared with the 
previous programme of screening from age 50 to 69. This builds on Chapter 2 by applying 
the deattenuated estimates of the relative risk reduction for breast cancer mortality and 
the risk of overdiagnosis to Australian breast cancer incidence and mortality data to 
estimate screening outcomes such as false positive results, mortality benefit and 
overdiagnosis. The aim was to provide women with information about the outcomes they 
could expect from the new policy, to help them make an informed choice about screening. 
This was published in the International Journal of Cancer. 
Chapter 3 is published as: 
Jacklyn G, Howard K, Irwig L, Houssami N, Hersch J, Barratt A. Impact of extending 
screening mammography to older women: information to support informed choices. 
International Journal of Cancer 2017.  
Available at: http://dx.doi.org/10.1002/ijc.30858 
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Chapter 4. Trends in stage-specific breast cancer incidence 
in New South Wales, Australia: insights into the effects of 
25 years of screening mammography 
This paper describes the results of an observational study to determine temporal trends in 
the stage-specific incidence of breast cancer in women who reside in New South Wales, 
Australia, between 1972 and 2012. The aim was to determine the effect screening 
mammography has had on the incidence of stage-specific breast cancer. This was 
published in the journal Breast Cancer Research and Treatment. 
Chapter 4 is published as: 
Jacklyn G, McGeechan K, Morrell S, Houssami N, Irwig L, Bell K, Barratt A. Trends in stage-
specific breast cancer incidence in New South Wales, Australia: insights from 25 years of 
screening mammography. Breast Cancer Research and Treatment 2017;166(3)843-54.  
Available at: https://doi.org/10.1007/s10549-017-4443-x 
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Chapter 5. Overdiagnosis in New South Wales, Australia 
due to screening mammography: an ecological study of 
breast cancer stage and overdiagnosis 
This paper used the data reported in Chapter 4 to conduct an ecological study and examine 
long-term trends in the incidence of early and late-stage breast cancer to estimate the risk 
of overdiagnosis attributable to screening mammography in women aged 50 years and 
older diagnosed in NSW, Australia. This paper is unpublished. 
Chapter 5 will be published in an international medical journal. 
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Overdiagnosis in New South Wales, Australia due to 
screening mammography: an ecological study of breast 
cancer stage and overdiagnosis 
Abstract 
Background 
The introduction of screening mammography in NSW, Australia, has been associated with 
an increase in the incidence of breast cancer for all stages. Our aim was to examine long-
term trends in the incidence of early and late-stage breast cancer to estimate the risk of 
overdiagnosis attributable to screening mammography. 
Methods 
We conducted an ecological study to examine trends in the incidence of stage-specific 
breast cancer in women aged 50 years and older diagnosed in NSW, Australia, from 1974 
to 2012. We estimated the background trend of increasing incidence using two approaches, 
the first based on the prescreening trend in women of screening age (50 years and older), 
and the second based on the contemporary trend in women too young to be screened (40 
to 44 years of age). From these trends, we estimated the expected age-standardised 
incidence of breast cancer, by stage at diagnosis, in the absence of screening, for women 
aged 50 years and over in the years since the national screening mammography program, 
BreastScreen, was introduced (1988 to 2012). We then calculated the difference in observed 
and expected incidence rates to determine the excess incidence of early-stage breast 
cancer and reduction in the incidence of late-stage disease. We estimated overdiagnosis 
as the incidence of overdiagnosed cancers (excess early-stage minus deficit in late-stage) 
as a percentage of total observed incidence in women who participated in screening during 
the screening period. 
Results 
For DCIS, localised and regional stages, there was a marked excess of observed incidence 
over expected. For distant metastases there was a deficit, with observed breast cancer 
incidence lower than expected observed. In the most recent three-year period for which 
data were available (2010 to 2012), there was an average of 310.1 cases per 100,000 women 
of DCIS, localised and regional breast cancer observed per year, compared to the expected 
annual incidence of 190.2 per 100,000 women, an absolute excess of 119.9 cases of early and 
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regional breast cancer. For distant metastases, there was an annual average incidence of 
42.9 cases per 100,000 women expected, but only 19.5 cases per 100,000 women observed, 
an absolute deficit of 23.4 cases per 100,000 women. We found overdiagnosis accounted 
for 26.1% to 29.5% of all breast cancers diagnosed since the introduction of screening. 
Conclusions 
We conclude that breast cancer screening has resulted in overdiagnosis of early-stage and 
regional breast cancer. We estimate that around six additional cases of early and regional 
breast cancer are detected for every distant metastatic breast cancer prevented.  
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Introduction 
Screening mammography aims to reduce mortality by detecting breast cancers at an 
earlier stage so more effective treatment can be offered. Thus, an effective screening 
program will increase the incidence of early-stage, preclinical breast cancers and decrease 
the incidence of late-stage cancers that were destined to present clinically and potentially 
cause death, were it not for screening. Yet some of this increase in incidence of early-stage 
disease will be the result of overdiagnosis – when a cancer is correctly identified and 
treatment is offered but this does not benefit the patient.1, 2 Under ideal circumstances 
there is little or no overdiagnosis, and incidence of advanced cancers is reduced by 
screening by about the same amount as early stage incidence is increased (Figure 1). At the 
opposite extreme, under a worst-case scenario, the amount of overdiagnosis is large, and 
there is no reduction in the incidence of advanced disease. 
 
Fig 1. Hypothetical illustration of an effective screening mammography program with 
zero to little overdiagnosis, with stage-specific breast cancer incidence from 1974-1983 
based on estimates from NSW women during the same period 
We observed increasing incidence of breast cancer in NSW for all-stages (DCIS, localised, 
regional and distant metastatic) following the introduction of screening mammography.3 
As there was an increase observed in all age groups, the observed data are inconsistent 
with an assumption of a constant burden of disease. This pattern contrasts with changes 
in stage specific incidence observed in the USA.4, 5 While no decrease in distant metastases 
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was detected in NSW, we did not take into account incidence trends in the absence of 
screening. 
An estimate of overdiagnosis in the range of 30% to 42% already exists for NSW.6 This 
figure, however, only captures the three-year period from 1999 through 2001, excludes 
DCIS, and the methods have not been replicated, making comparison with other studies 
unreliable. We wanted to explore a different approach to estimate overdiagnosis to 
provide clarification with international studies that use similar methods5, 7 and present a 
contemporary estimate that reflects current screening practice, as well as the entire 
screening period. 
The state of New South Wales (NSW) in Australia provides a unique opportunity to 
examine the effects of screening on the incidence of late-stage breast cancer and 
overdiagnosis, as it is the only jurisdiction in Australia with historical records of stage at 
diagnosis. From 1988, the national breast cancer screening program, BreastScreen, began 
offering free biennial screening to NSW women over age 40 using two-view 
mammography with double-reading. From 1991 to 2012, women aged 50 to 69 years were 
targeted via letters of invitation. Biennial participation rates for NSW women in the target 
age group have ranged from 51% to 56%. Participation for eligible women outside 50 to 69 
years has been more variable, with higher rates in the early years of the program at around 
22%, dropping sharply in 2005 to around 7%. While the overall burden of breast cancer in 
NSW has increased, we do not know if this has translated into a decrease in more advanced 
cancers. Our aim was to examine the association of screening with changes in the 
incidence of early and late stage breast cancer in NSW between 1988 and 2012 to estimate 
the level of overdiagnosis attributable to the NSW breast screening program during this 
time. 
Methods 
Overview 
To analyse trends in early and late-stage breast cancer at diagnosis in NSW following the 
introduction of screening, we obtained data on the number of stage-specific cases of breast 
cancer among NSW women from 1972 through 2012 and screening mammography 
attendance from 1988 onwards. Our approach is based on methods previously reported by 
Bleyer and Welch (2012), with modification for local data.5 To calculate the number of 
excess early-stage cancers and the reduction in late-stage cases in women aged 50 years 
and older who regularly attend screening, we determined expected counts in the absence 
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of screening and compared these with observed data. To estimate expected counts we used 
two approaches. 
Primary analysis 
1. Prescreening trend: Poisson regression modelling of historical trends of stage-
specific breast cancer prior to the introduction of mammography in women aged 
50 years and older from 1974 to 1983 to estimate annual expected counts from 1988 
to 2012. 
Secondary analysis 
2. Contemporary trend: stage-specific incidence trends in NSW women who did not 
attend screening regularly (age 40 to 44 years) from 1988 to 2012, applied to the 
baseline stage-specific incidence in women aged 50 years and older before 
screening (1980-1983). 
We adjusted the observed estimates of breast cancer for the effects of increasing use of 
hormone replacement therapy (HRT), which coincided with the introduction of screening 
mammography. We then calculated the excess (or deficit) observed counts relative to the 
expected in each calendar year. We captured the compensatory drop in incidence due to 
lead time by including cancer cases in women who were older than the upper age limit of 
the target age group of the screening program. Additionally, we analysed trends over 25 
years, to allow time for successive cohorts of women of screening age to cease screening 
as they aged out of the target age group. Twenty-five years also allows ample time for the 
excess of early-stage cancers to transform into a reduction in late-stage disease, if 
screening is effective. We standardised rates by 5-year age groups to the 2001 Australian 
population. We performed our analyses using SAS 9.4 and Microsoft Excel software. 
Data sources 
Breast cancer cases 
We obtained de-identified individual data for all cases of female breast cancer from the 
NSW Cancer Registry (NSWCR) diagnosed from 1972 to 2012. The NSWCR contains 
records of all new diagnoses of cancer in residents of NSW. The Registry has been 
collecting cancer data since 1972 with mandatory pathology reporting from 1986 and 
almost 100% coverage. Breast cancer was histologically verified for over 99% of carcinoma 
in situ cases and approximately 95% of invasive lesions. It is the only cancer registry in 
Australia that contains information on degree of spread from 1972 onwards. Carcinoma in 
situ of the breast has been notifiable in NSW since 1992 and completeness of this data 
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before then was estimated to be around 90%.8 Annual estimates of the population of 
women were obtained from the Australian Bureau of Statistics.9 Our research protocol was 
approved by the research ethics board of the NSW Population & Health Services Research 
Ethics Committee. 
Breast cancer stage is assigned from the highest degree of spread within four months of 
the diagnosis. The NSW summary stage indicator is equivalent to the US Surveillance and 
Epidemiology End Results historic stage A (SEER SS2000).10 The variable is used to classify 
the degree of cancer spread as: in situ (a neoplasm that remains in the position of origin 
and there is no penetration of the basement membrane); localised (node-negative cancer 
confined to the breast); regional (spread to adjacent tissues and organs and/or regional 
lymph nodes); distant metastases (spread beyond the breast to distant organs or lymph 
nodes); and unknown (invasive breast cancer with an unknown stage at diagnosis). 
Screening mammography attendance 
The national screening mammography program, BreastScreen, has been established in 
NSW for almost 30 years. From 1988 through 2012, women aged 40 and older were eligible 
to attend free biennial screening using two-view mammography with double reading, with 
those aged 50 to 69 years targeted via letters of invitation. To contextualise our study and 
facilitate interpretation of our findings, data on annual numbers of mammographic 
examinations among women aged 40 years and older were obtained from BreastScreen 
NSW for 1988 to 2012 (Figures 2A and 2B). These data did not include private screening 
outside of the national program BreastScreen NSW, and an additional 6.9% of NSW 
women aged 50 to 69 years have a government-funded bilateral mammogram annually 
through the Medicare Benefits Schedule (MBS), many of whom are likely to be 
asymptomatic and the mammography performed for screening purposes.11 To capture 
screening outside of the program, we obtained data on the number of bilateral 
mammograms in NSW reimbursed by the MBS from the Department of Human Services 
since 1984 (MBS item number 2734 for 1984 to 1991 and 59300 for 30 November 1991 
onwards). The rate of MBS screening peaked around 1991, declined until 1996 and has been 
relatively stable since (Figures 2A and 2B). The proportion of MBS-funded bilateral 
mammograms in women aged 50 to 69 years performed for screening purposes has been 
estimated to be around 53%,11 but could be higher. 
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Observed incidence in women exposed to screening 
During the screening period from 1988 to 2012, we identified 105,051 women diagnosed 
with breast cancer and of these 79,133 were age 50 years and older. We excluded cases that 
were not histologically verified (2,952) and where the stage was unknown (n=5,933), 
leaving 70,248 women aged 50 years and older: 8,956 carcinoma in situ; 36,201 localised; 
21,676 regional; 3,415 metastatic. We limited the in situ category to ductal carcinoma in 
situ (DCIS) (n=8,116). We defined DCIS according to the following International 
Classification of Diseases for Oncology (ICDO-3) morphology codes: 8201/2, 8230/2, 
8500/2, 8501/2, 8503/2, 8507/2, 8521/2, 8522/2 and 8523/2. 12, 13 
We excluded all other categories of carcinoma in situ of the breast, including lobular 
carcinoma in situ (LCIS), as they are typically an incidental finding and generally do not 
present clinically or on imaging (n=840). We defined early-stage cancer as DCIS or 
localised disease, and late-stage cancer as regional or distant metastatic disease. 
Expected incidence in unscreened women 
Primary analysis: prescreening trends in women aged 50 years and older 
Expected incidence trends for unscreened women aged 50 years and older were based on 
the ten years before the introduction of government-funded mammography from 1974 to 
1983. Pooling data over ten years prevent results being influenced by annual fluctuations 
and improves accuracy in predicting outcomes.14 We did not use 1972 to 1973 as the NSW 
Cancer Registry was established in 1972 and the first two years in which breast cancer 
incidence was recorded were spuriously low. During 1974 to 1983, the incidence of 
metastatic breast cancer was stable. DCIS was rare, consistent with the limited use of 
screening mammography at the time. There was a small but steady increase in localised 
and regional breast cancer incidence at a rate of around 3% per year. 1983 was chosen as 
the end date because, in 1984, government-funded bilateral mammography became 
available under Medicare. As a consequence, there was a limited amount of private 
screening and breast cancer incidence in women aged 50 years and older began to rise 
(Figure 2).15 
We used Poisson regression to analyse cases of early-stage (DCIS and localised), regional 
and distant breast cancer by 5-year age groups in unscreened women older than 50 years 
from 1974 to 1983. We extrapolated to 2012 by modelling time in years since 1974, using an 
offset to account for the age-specific population sizes. As few cases of DCIS were recorded 
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before screening (n=38), we split the number of expected counts for early-stage breast 
cancer according to the proportion that was DCIS before 1983 (less than 1% of early-stage 
breast cancer) and localised. For a valid comparison of the expected and observed 
incidence, we converted counts into incidence rates that were age-standardised by the 
direct method using the Australian 2001 standard population. 
Secondary analysis: contemporary trends in younger unscreened women 
Before the introduction of screening mammography, there was a similar pattern of a 
gradual increase in the burden of disease over time for younger and older women (Figure 
2A-2C). As this suggests there was no major difference in confounders for different age 
groups, we used a contemporary adjustment for changes in important risk factors for 
breast cancer by examining trends in women aged 40 to 44 years, who are generally 
unexposed to screening (Appendix A). Women younger than 40 years at average risk of 
breast cancer are not eligible for screening and those younger than 50 years are eligible 
but not invited. From 2011 to 2012, around 6% of NSW women aged 40 to 44 years 
participated in the BreastScreen NSW program, and the rate has never been above 10%.16 
To estimate expected rates in the absence of screening for women over 50 years of age, we 
calculated the average annual percentage change for early-stage, regional and distant 
breast cancer in women aged 40 to 44 from 1988 to 2012, then applied the corresponding 
calculations to the age-standardised average annual stage-specific incidence of breast 
cancer for women older than 50 years from 1979 to 1983. Again, as few cases of DCIS were 
recorded before screening, we calculated the average annual percentage change in 
incidence for early-stage breast cancer (DCIS and localised combined), and applied this 
number to the average annual incidence for DCIS and localised disease. 
Adjustment for the effects of hormone replacement therapy 
Combined HRT use is a known risk factor for breast cancer 17 and some of the observed 
increase in incidence following the introduction of screening up to 2004 would be due to 
its effects. HRT use became increasingly popular in the early 1990s and prescriptions in 
Australian women older than age 50 increased from 1996 to 2001, but dropped by 40% 
between 2001 to 200318, 19 following the publication of the Women’s Health Initiative trial 
in 2002.20 HRT use has remained relatively stable since 2005.21 This sharp drop in combined 
HRT use corresponded with a decrease in breast cancer incidence in subsequent years.22 
As breast cancer risk returns to the population risk within two years after stopping HRT,23 
if the annual estimate of incidence from 1988 to 2004 was higher than the three-year period 
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after the effects of HRT should have ceased (2005 to 2007), we adjusted for the effects of 
HRT by capping the observed annual incidence at the 2005 to 2007 estimate. 
Adjustment for lead time 
Our approach allows for any temporal reduction in the incidence of breast cancer due to 
earlier diagnosis in women no longer screened. The advance in time of cancer diagnosis 
due to screening (lead time) causes a temporary increase in cancer incidence. Once 
screening stops, the rate of detection of cancers in the previously screened group should 
be less than the unscreened group, compensating for the earlier increase in incidence due 
to lead time. This phenomenon is called the “compensatory drop”.24 Estimates of average 
lead time of breast cancer range from one to three years.25-27 Estimates based on 
progressive pre-clinical cancers are shorter, at around one year, with maximum lead time 
approximately four years.24 Thus including all women past the screening age captures the 
compensatory drop. Further, by analysing 25 years of data, we allow sufficient follow-up 
time for the screening program to have reached a “steady state”, where women entering 
the program approximately balance those leaving it, allowing for equilibrium between the 
initial incidence peak and the later compensatory drop. 
Estimating overdiagnosis 
For 1988 and every year after, we calculated the absolute difference in the observed 
incidence of stage-specific breast cancer relative to the expected estimate in the absence 
of screening. To calculate the cumulative increase in incidence of early-stage breast 
cancers and the cumulative reduction in the incidence of late-stage breast cancers 
attributable to screening mammography, we summed the data from 1988 to 2012. We then 
expressed overdiagnosis as the incidence of overdiagnosed cancers (excess early-stage 
minus deficit in late-stage) as a percentage of total observed incidence in women who 
participated in screening during the screening period.28 Our primary analyses included 
both DCIS and invasive breast cancers. To compare the contributions of different stages 
to total overdiagnosis, we also reported the breakdown of excess cumulative incidence by 
stage. 
Unknown stage at diagnosis 
7.8% of all histologically verified breast cancers diagnosed in women aged 50 years and 
older from 1988 to 2012 were classified as unknown stage. We excluded these from our 
primary analysis but conducted four sensitivity analyses to allow for unknown stage of 
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breast cancer. For observed and expected incidence trends we included data on unknown 
stage of breast cancer. We allocated observed counts of unknown stage as a proportion of 
each invasive stage (localised, regional and distant), as well as recategorising all counts of 
unknown stage separately as localised, regional and then distant metastases. 
Results 
69,408 women aged 50 years and older were diagnosed with histologically verified DCIS 
or invasive breast cancer between 1988 and 2012. 
Changes in incidence of breast cancer 
Figure 2 shows temporal trends in the observed incidence of early- and late-stage breast 
cancer and annual participation in screening mammography in NSW. Among women aged 
50 years and older, the use of screening mammography began in 1988, increasing with the 
widespread introduction of BreastScreen NSW around 1991. Participation has remained 
relatively stable since 1996 (Figure 2A) at around 27% annually for BreastScreen NSW (54% 
biennial participation) and 7% for government-funded bilateral mammography. This 
increasing participation in screening mammography coincided with a sharp increase in 
the incidence of early-stage breast cancer. We did not observe a decrease in the incidence 
of late-stage breast cancer at any time since the introduction of screening. Over the same 
period, in women aged 40 to 49, there was some use of screening mammography which 
decreased dramatically in 2005 (Figure 2B). In women younger than age 50 we also 
observed a background increase in the incidence of both early- and late-stage breast 
cancer but to a lesser extent than older women. 
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A. Women aged 50 years and older 
Annual screening participation 
 
Note: NSW women are offered screening mammography every two years  
 
Incidence of Early- and Late-Stage Breast Cancer in women 50 years of age and older, 
1972–2012  
 
Pi
lo
t s
cr
ee
ni
ng
 
Br
ea
st
Sc
re
en
 N
SW
 
 
 
 
64 
B. Women aged 40-49 years 
Annual screening participation 
 
Note: NSW women are offered screening mammography every two years  
 
Incidence of Early- and Late-Stage Breast Cancer in Women 40 to 49 years of age, 1972–
2012  
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C. Women younger than 40 years of age 
Incidence of Early- and Late-Stage Breast Cancer in Women younger than 40 years of 
age, 1972–2012  
 
Note:  NSW women younger than 40 years are ineligible to screen 
Data is presented on a smaller y-axis to previous plots as breast cancer is rare in women younger than 40 years 
of age 
 
Fig 2. Use of Screening Mammography and Incidence of Early- and Late-Stage Breast 
Cancer in Women from NSW, Australia, 1972–2012 
Rates age-standardised to the Australian population 2001 
Early stage = ductal carcinoma in situ and localised breast cancer;  Late-stage = regional and distant metastatic breast 
cancer  
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Table 1 shows the absolute changes in the annual stage-specific incidence of breast cancer 
before and after screening mammography in women aged 50 years and older. Over 30 
years, the incidence of early-stage breast cancer increased from 80.7 to 203.5 per 100,000 
in women aged 50 years and older. Late-stage breast cancer increased from 64.9 to 126.1 
per 100,000 women. The substantial increase in cases of early-stage breast cancer reflects 
increased detection of both in situ and localised tumours. The increase in cases of late-
stage breast cancer largely reflects an underlying temporal trend of increasing detection 
of regional disease, whereas the rate of distant metastases remained relatively stable 
(Figure 3). 
Table 1. Absolute change in the incidence of stage-specific breast cancer among 
women aged 50 years and older after the introduction of screening 
 
 Average Annual Breast Cancer Incidence 
 
Before 
mammography 
(1981-1983) 
After 
mammography 
(2010-2012) 
Absolute 
change 
 number of cases per 100,000 women 
Early-stage breast 
cancer    
    DCIS 0.6 45.4 44.8 
    Localised  80.2 158.1 78.0 
    Total 80.7 203.5 122.8 
Late-stage breast cancer    
    Regional  52.4 106.6 54.2 
    Distant metastases 12.6 19.5 7.0 
    Total 64.9 126.1 61.2 
Rates age-standardised to the Australian population 2001 
DCIS = ductal carcinoma in situ 
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Fig 3. Age-standardised incidence of stage-specific breast cancer in NSW women aged 
50 years and older, 1972-2012 
Rates age-standardised to the Australian population 2001 
DCIS = ductal carcinoma in situ 
Overdiagnosis 
Table 2 shows the average annual incidence of stage-specific breast cancer observed since 
the introduction of screening in women over 50 and the expected incidence if women had 
not been exposed to screening, as well as estimates of excess incidence. After allowing for 
the increasing burden of disease over time expected in the absence of screening, our 
results show that screening was associated with reduced rates of distant metastatic breast 
cancer, but it was not associated with a decrease in regional breast cancer. In our primary 
analysis (using an expected incidence based on prescreening trends in women aged 50 
years and older), there was a net increase in late-stage breast cancer. In our secondary 
analysis (using contemporary trends in women aged 40 to 44 years who were generally not 
exposed to screening), the decrease in distant metastases compensated for the excess cases 
of regional breast cancer, resulting in a net decrease in late-stage disease. 
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Table 2. Average annual incidence of breast cancer in NSW women aged 50 years and 
older during the screening period 
 
  
Average Breast Cancer Incidence  
(per 100,000 women) 
 Observed 
Method DCIS Localised Regional Distant 
 2010-2012 
Prescreening trend  45.4 158.1 106.6 19.5 
Contemporary trend 45.4 158.1 106.6 19.5 
 
Over the entire screening period (1988-2012) 
Prescreening trend  31.4 142.0 86.7 13.0 
Contemporary trend 31.4 142.0 86.7 13.0 
 Expected without screening 
Method DCIS Localised Regional Distant 
 2010-2012 
Prescreening trend  1.3 129.6 59.3 42.9 
Contemporary trend 0.7 96.1 84.5 72.1 
 
Over the entire screening period (1988-2012) 
Prescreening trend  1.1 107.9 54.7 28.0 
Contemporary trend 0.6 89.6 70.6 40.1 
 
Excess cancers 
Method DCIS Localised Regional Distant 
 2010-2012 
Prescreening trend  44.0 28.6 47.2 -23.4 
Contemporary trend 44.7 62.0 22.1 -52.6 
 Over the entire screening period (1988-2012) 
Prescreening trend  30.3 34.2 32.1 -14.9 
Contemporary trend 30.8 52.4 16.2 -27.0 
Observed incidence excludes excess cases associated with the use of Hormone Replacement Therapy 
(1988-2005) 
Rates age-standardised to the 2001 Australian population 
DCIS = ductal carcinoma in situ 
  
Table 3 shows the number of women overdiagnosed due to screening mammography. 
When expected incidence in unscreened women was based on prescreening trends in 
those aged 50 years and older, we estimated 3,562 excess cases of breast cancer during 2010 
to 2012 and 20,743 over the entire screening period. When expected incidence in 
unscreened women was based on contemporary trends in those aged 40 to 44 years, there 
were 2,812 excess cases of breast cancer during 2010 to 2012 and 18,285 over the entire 
screening period. 
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Table 3. Cumulative number of women aged 50 years and older diagnosed with breast 
cancer during the screening period in NSW, Australia 
 
  
Women diagnosed with breast cancer 
(n) 
 Observed 
Method DCIS Localised Regional Distant 
 
2010-2012 
Observed cases 1677 5843 3937 721 
 Over the entire screening period (1988-2012) 
Observed cases 8175 35352 21800 3345 
 
Expected without screening 
Method DCIS Localised Regional Distant 
 2010-2012 
Prescreening trend  48 4788 2192 1587 
Contemporary trend 26 3551 3122 2666 
 Over the entire screening period (1988-2012) 
Prescreening trend  271 26960 13522 7176 
Contemporary trend 159 22129 17625 10478 
 Excess cancers 
Method DCIS Localised Regional Distant 
 2010-2012 
Prescreening trend  1628 1055 1745 -866 
Contemporary trend 1651 2292 814 -1945 
 Over the entire screening period (1988-2012) 
Prescreening trend  7904 8392 8278 -3831 
Contemporary trend 8016 13223 4175 -7129 
Excludes excess cases associated with the use of Hormone Replacement Therapy from 1988-2005 
Counts age-standardised to the 2001 Australian population 
DCIS = ductal carcinoma in situ 
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After converting to age-standardised incidence rates, this corresponds to 23.1% to 29.3% 
of all breast cancers in women aged 50 years and older being overdiagnosed during 2010 
to 2012, and between 26.1% and 29.5% over the entire screening period (1988 to 2012) 
(Table 4). We estimate that approximately six additional cases of early-stage and regional 
breast cancer are detected for every distant metastatic breast cancer prevented. 
Table 4. Stage-specific excess cumulative incidence and estimated overdiagnosis in 
NSW women aged 50 years and older 
 
  Excess cumulative incidence (%) 
Method DCIS Localised Regional Distant 
Overdiagnosi
s 
 
2010-2012 
Prescreening trend  13.4% 8.7% 14.3% -7.1% 29.3% 
Contemporary trend 13.6% 18.8% 6.7% -15.9% 23.1% 
 Entire screening period (1988-2012) 
Prescreening trend  10.9% 12.3% 11.6% -5.4% 29.5% 
Contemporary trend 11.1% 18.9% 5.8% -9.8% 26.1% 
Excess cumulative incidence % = excess cumulative incidence /  cumulative observed incidence among all women 
invited to screening 
Overdiagnosis % = excess incidence (DCIS + localised + regional + distant metastases) / cumulative incidence among 
all women invited to screening 
DCIS = ductal carcinoma in situ 
   
Sensitivity analysis 
Similar patterns of overdiagnosis were observed when we included breast cancer cases 
with an unknown stage at diagnosis. After allowing for the increasing burden of disease in 
unscreened women over time, screening mammography was associated with increased 
detection of early-stage and regional breast cancer and a decrease in distant metastatic 
disease. Including unknown stage increased the estimate of overdiagnosis. During 2010 to 
2012 the proportion of overdiagnosed breast cancers was estimated to be as low as 27.8% 
and as high as 42.3% when we included unknown stage. Over the entire screening period 
estimates ranged from 31.4% to 37.7% (Table 5). 
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Table 5. Sensitivity analysis of percentage risk of overdiagnosis in women aged 50 
years and older 
 
  Excess cumulative incidence (%) 
Method DCIS Localised Regional Distant Overdiagnosis 
 Unknown stage proportioned between invasive stages 
 2010-2012 
Prescreening trend   12.9% 11.6% 15.2% -6.4% 33.3% 
Contemporary trend 13.1% 18.3% 5.1% -15.3% 21.1% 
 Entire screening period (1988-2012) 
Prescreening trend   10.1% 14.4% 12.8% -4.8% 32.5% 
Contemporary trend 10.2% 19.0% 5.5% -8.7% 26.0% 
 Localised combined with unknown 
 2010-2012 
Prescreening trend   12.9% 12.7% 13.8% -6.8% 32.5% 
Contemporary trend 13.1% 29.3% 6.5% -15.4% 33.5% 
 Entire screening period (1988-2012) 
Prescreening trend   10.1% 15.5% 10.6% -5.0% 31.3% 
Contemporary trend 10.2% 26.9% 5.4% -9.0% 33.5% 
 
Regional combined with unknown 
 2010-2012 
Prescreening trend   12.9% 8.3% 16.0% -6.8% 30.3% 
Contemporary trend 13.1% 18.1% 12.0% -15.4% 27.8% 
 
Entire screening period (1988-2012) 
Prescreening trend   10.1% 11.3% 15.4% -5.0% 31.8% 
Contemporary trend 10.2% 17.4% 11.9% -9.0% 30.6% 
 Distant Metastases combined with unknown 
 
2010-2012 
Prescreening trend   12.9% 8.3% 13.8% 0.1% 35.2% 
Contemporary trend 13.1% 18.1% 6.5% 4.7% 42.3% 
 Entire screening period (1988-2012) 
Prescreening trend   10.1% 11.3% 10.6% -0.3% 31.8% 
Contemporary trend 10.2% 17.4% 5.3% 3.0% 35.9% 
Excess cumulative incidence % = excess cumulative incidence /  cumulative observed incidence among all women 
invited to screening 
Overdiagnosis % = excess incidence (DCIS + localised + regional + distant metastases) / cumulative incidence among 
all women invited to screening 
DCIS = ductal carcinoma in situ 
 
72 
Discussion 
After almost 30 years of screening mammography in NSW, we would expect to see a 
decrease in the incidence of late-stage breast cancer. While we observed a background 
increase in breast cancer incidence for all ages, this increase is most marked in women of 
screening age, where there was a considerable increase in the incidence of early-stage 
disease that was not matched by a commensurate decrease in the rate of late-stage breast 
cancer. Taking into account the underlying increase in the burden of disease, we found 
that screening contributed to a reduction in the expected incidence of metastatic breast 
cancer but did not reduce the incidence of regional breast cancer. While the prevention of 
almost 4,000 women being diagnosed with metastatic breast cancer is a welcome benefit, 
our results indicate that this has been at the cost of over 24,000 women being 
overdiagnosed and potentially overtreated. This overdiagnosis is not confined to non-
invasive breast cancers, it includes localised and regional tumours. Our results suggest 
that screening is associated with approximately six additional cases of early and regional 
breast cancer detected for every breast cancer with distant metastasis prevented. Although 
observational methods leave residual uncertainty, a recent review concluded that well-
designed ecological and cohort studies are the most appropriate method for monitoring 
contemporary cancer screening programs.29 Our estimate of overdiagnosis is large and the 
similar results from our primary and secondary analyses support our conclusions. Further, 
our findings are consistent with previous estimates of overdiagnosis in NSW.6 The ratio of 
benefit to harm is similar to outcomes from a recent modelling analysis of the screening 
mammography program in Australia based on application of estimates from randomised 
controlled trials to local data.30 
Strengths and limitations 
The NSW Cancer Registry is a large, population-based data set spanning over 40 years, 
with virtually complete case ascertainment and high rates of histological confirmation. 
Notification of cancer to the registry has been mandatory since 1972 ensuring high 
coverage of population incidence. It is one of the few international registries that has 
collected data on stage from inception. These factors make the NSW Cancer Registry a 
unique dataset for studies of cancer epidemiology. 
Although our study is ecological in design and uses aggregate data, we were able to obtain 
objective data on the number of women screened by BreastScreen NSW, as well as from 
private clinics from the outset of government-funded mammography to capture screening 
participation outside of the program. Thus, we have a complete and accurate picture of 
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the timing and amount of exposure to screening mammography in NSW women to help 
design and interpret our study. 
Screening mammography should have an immediate effect by increasing incidence 
directly after introduction, and a delayed effect of reducing incidence in women who have 
left the screening programme. We provide a long follow-up, utilising 25 years of data 
during the screening period, which allows for these immediate and delayed effects. We 
further account for lead time by including women older than the upper age limit of the 
target screening group. As estimates of lead time average between one and three years, it 
is possible that we have over-adjusted for lead time by including women 80 years and over 
who are much older than the screening target age. 
All methods used to monitor the benefits and harms of population screening programs are 
imprecise. While our observational study design may be more applicable than randomised 
controlled trials, it is more prone to biases. As screening mammography has been 
established throughout Australia for almost 30 years, the incidence of breast cancer in the 
absence of screening cannot be observed without selection bias. This makes disentangling 
contributors to changes in breast cancer incidence unrelated to screening difficult. In 
women aged 50 years and older, the majority of risk factors for breast cancer are associated 
with a woman’s lifetime exposure to oestrogen and progesterone, including reproductive 
characteristics, postmenopausal obesity and HRT use. The risk of breast cancer increases 
by around 30% due to reproductive characteristics such as early age at menarche, late age 
at first full-term pregnancy, nulliparity, and late age at menopause.31-33 In postmenopausal 
women, obesity increases the risk of breast cancer,34-36 with a greater effect in women who 
do not use HRT (Relative Risk 1.4) compared to those who do (Relative Risk 1.2).37  
There has been a long-term trend of increasing obesity in NSW. Before screening the 
prevalence of obesity in women aged 50 and older was rising, increasing from 11.5% in 1980 
to 15.1% by 1983; data prior to 1980 are not available.38, 39 Over the screening period from 
1988 to 2012, obesity prevalence continued to increase from 20.2% to 32.9%.40, 41 Changes 
in reproductive factors also occurred during the 20th century with gradual trends towards 
fewer children, later age at first birth, and earlier menarche in many developed countries 
including Australia.6 Changes in the prevalence of postmenopausal obesity and 
reproductive risk factors throughout the 20th century are therefore likely to have 
influenced patterns of breast cancer in NSW. As these effects would have been operating 
throughout the 1970s and 1980s, much (but perhaps not all) of these effects should have 
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been captured in our primary analysis to adjust for confounders using the prescreening 
trend between 1974 and 1983. 
HRT use as a risk factor for breast cancer is well established.42 As HRT use was uncommon 
prior to screening, its effects were not captured in our prescreening trend. We dealt with 
increasing exposure to HRT that coincided with the introduction of screening by capping 
observed incidence of breast cancer from 1988 to 2005, based on previously published 
methods.5 Although there is evidence that the effect of HRT on breast cancer incidence 
had ended by 2005,22 the onset is less certain. To ensure we adequately adjusted for HRT, 
we chose to cap the incidence of stage-specific breast cancer from the start of BreastScreen 
NSW; this may have resulted in an over-adjustment. 
Lastly, regular alcohol consumption increases the risk of breast cancer (Relative Risk 1.3 to 
1.6).43 The prevalence of alcohol intake in NSW women has remained relatively stable over 
time, with a slight decrease observed in recent years.38, 39, 41 Therefore any increase in breast 
cancer due to the effects of alcohol intake should be stable and captured in our expected 
incidence of unscreened women. 
We used two different methods to allow for the underlying increase in incidence of breast 
cancer due to these risk factors and provide perspective on the considerable uncertainty 
when estimating the expected incidence that would have been observed in the absence of 
screening. Our primary method of using prescreening trends in women aged 50 years and 
older is likely to better reflect expected unscreened incidence. It is based on a period when 
mammography was rare and allows for trends in important risk factors relevant to this age 
group such as postmenopausal obesity. Using contemporary trends in women younger 
than the screening age group is more imprecise. These women are generally 
premenopausal so their risk of breast cancer is different. In Australia, they are not 
completely representative of an unscreened population as a small proportion of women 
aged 40 to 44 attend screening mammography which would bias our estimate of 
overdiagnosis in favour of screening. And while our estimates of expected incidence 
should reduce confounding by allowing for the underlying increase in breast cancer due 
to other causes, we cannot rule out that the observed rise in regional breast cancer was 
influenced by changes in the prevalence of unknown risk factors for breast cancer 
unaccounted for in our analysis. 
Data on unknown stage of breast cancer in women aged 50 years and older fluctuated over 
time. Of all invasive breast cancers, 10% were unknown stage before screening (1974 to 
1983), increasing to 16% between 1988 to 1996, before decreasing to 5% during 2006 to 
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2012. The rise in the proportion of cases with an unknown stage coincided with the roll-
out of screening mammography and a sharp increase in localised disease.3 Because there 
was a transient, concurrent rise in unknown stage with the introduction of screening, the 
estimates of overdiagnosis taken from our sensitivity analyses are greater than our primary 
and secondary analyses. This suggests that the recategorisation of unknown stage to 
localised may better reflect the percentage risk of overdiagnosis (Table 5). 
Effects on metastatic disease 
We previously documented increases in all stages of breast cancer in NSW. Allowing for 
expected increases in breast cancer due to factors other than screening, our findings 
suggest that screening prevented 3,831 cases of metastatic disease at diagnosis (15%). This 
result is consistent with estimates of breast cancer mortality reduction from randomised 
controlled trials44 and local observational studies.45 
The assigned summary stage at diagnosis does not change if a cancer recurs or progresses. 
Thus summary stage data does not account for the effect of early detection and treatment 
of in situ, localised or regional breast cancer on the subsequent risk of progression to 
metastatic cancer. Currently, cancer registries do not routinely record this information. 
Therefore, our assessment of the reduction in metastatic disease may be an underestimate 
as it does not capture the gains for women with early breast cancer regarding their risk of 
developing metastatic breast cancer. 
Comparison with other studies 
Both the Morrell (2010)6 estimate of overdiagnosis in NSW of 30% to 42%, and our 
contemporary estimate of 26% to 30%, are considerably higher than South Australian 
estimates of overdiagnosis (12% to 14%).46, 47 These differences may reflect different time 
periods, populations and practices in the jurisdictions, as well as different study methods. 
Our analysis is consistent with two studies from the USA that found screening 
mammography is associated with a large increase in early-stage breast cancer and a 
decrease in late-stage disease,4, 5 though rates of regional breast cancer in NSW, Australia, 
are currently higher than they have ever been in the USA. Stage-specific trends in Europe 
show a different pattern; screening mammography has increased the incidence of early-
stage breast cancer without reducing the incidence of late-stage tumours.7, 48-53 
International estimates of overdiagnosis using observational data report similar findings.54, 
55 A literature review from Europe found excess invasive cancers to account for 1% to 10%, 
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though this was expressed as a proportion of expected incidence in the absence of 
screening.56 A more recent review from the International Agency for Research on Cancer 
(IARC) Working Group found reliable estimates of overdiagnosis in the range of 2% to 
25% for invasive cancer.57 
Implications 
Our study provides further evidence that screening mammography is a double-edged 
sword; it can deliver a valuable benefit to women by reducing the risk of being diagnosed 
with metastatic breast cancer but it can cause substantial harm through overdiagnosis. 
Thus the potential benefit comes at a great cost to individuals and our health care system. 
It is imperative that women are aware of the likely magnitude of overdiagnosis and 
consequences of overtreatment so they can make an informed decision about screening. 
Current brochures and invitations to screening mammography in NSW inform women 
that a cancer may be detected that may not have become life threatening. But the materials 
emphasise benefits and minimise risks, and do not provide women with an objective 
numerical comparison to weigh up the benefit harm trade-off.58 With the adoption of 
more sensitive screening technologies such as digital mammography and potentially 
tomosynthesis, it is unlikely that we can prevent overdiagnosis. But we can mitigate the 
harm through de-escalation of treatment for low-risk cancers and further research into 
biomarkers and other novel methods to identify which screen-detected cancers would go 
on to cause harm and which ones are destined to remain dormant. 
Conclusions 
Screening mammography in NSW has resulted in a reduction in the incidence of 
metastatic breast cancers but with a substantial increase in the detection of early-stage 
and regional breast cancers. We estimate that around six additional cases of early and 
regional breast cancer are detected for every metastatic breast cancer prevented. Women 
should be provided with balanced information on the risks and benefits so they can make 
a fully informed decision about screening. 
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Appendix A 
Incidence of Early- and Late-Stage Breast Cancer in Women 40 to 45 years of age, 1972–
2012 
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Chapter 6. Carcinoma in situ of the breast in New South 
Wales, Australia: current status and trends over the last 40 
years 
This paper describes the results of an observational study to determine temporal trends in 
the incidence of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) in 
New South Wales women who received a diagnosis from 1972 to 2012. The aim was to 
determine the effect of population-based screening mammography on the incidence of 
carcinoma in situ of the breast. This was published in the journal The Breast. 
Chapter 6 is published as:  
Jacklyn G, Morrell S, McGeechan K, Houssami N, Irwig L, Pathmanathan N, Barratt A. 
Carcinoma in situ of the breast in New South Wales, Australia: current status and trends 
over the last 40 years. The Breast 2017;37(2018):170-178. 
Available at: https://doi.org/10.1016/j.breast.2017.08.005 
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Chapter 7. Overdiagnosis due to screening mammography 
for women aged 40 years and older [Protocol] 
This paper outlines the methodology for a systematic review that aims to estimate 
overdiagnosis using international estimates from both randomised and non-randomised 
studies. This will be published in the Cochrane Database of Systematic Reviews. 
Chapter 7 is currently under review as: 
Jacklyn G, McGeechan K, Houssami N, Bell K, Glasziou P, Barratt A. Overdiagnosis due to 
screening mammography for women aged 40 years and older [Protocol]. Cochrane 
Database of Systematic Reviews (Revised manuscript submitted for publication) 
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Overdiagnosis due to screening mammography for women 
aged 40 years and older 
Background 
Description of the condition 
Breast cancer is the most common cancer in women worldwide and a leading cause of 
cancer death (Ferlay et al, 2015). During the late 20th century screening mammography was 
introduced in developed countries on the evidence that it reduced breast cancer mortality, 
without adequate consideration or knowledge of potential harms. During this time there 
was an increase in breast cancer incidence in women aged 50-69 years. This was partly due 
to changes in risk factors such as alcohol intake, reproductive history, obesity and 
hormone therapy use. (Bray et al, 2004; Jemal et al, 2010) but also, as has now become 
apparent, because of widespread uptake of screening mammography and resulting 
overdiagnosis. Carter et al (Carter et al, 2016) provide a broad definition of overdiagnosis: 
“when a health-related problem is correctly identified and labelled (an intervention may 
also be offered) but this does not benefit”. In the context of cancer screening, 
overdiagnosis is the detection of cancer by screening that would never cause symptoms or 
harm in the absence of screening (Baker et al, 2014; Marcus et al, 2015; Welch & Black, 
2010). Overdiagnosis involves the interaction between the biology of preclinical cancer and 
competing risks for mortality. Thus, it can occur through the detection of non-progressive 
preclinical breast cancer, or through the detection of progressive, preclinical cancer in 
women with limited life expectancy. 
Overdiagnosis is now acknowledged as the major harm of screening mammography 
(Independent UK Panel on Breast Cancer Screening, 2012). It should not be confused with 
a false positive result: when a screening test detects an abnormality but with further 
investigation, no cancer is found. By contrast, overdiagnosis is a cancer diagnosis which is 
correct according to contemporary professional standards for pathology reporting and 
classification. As it is not possible to identify individuals who will benefit or be harmed by 
early detection and treatment, everyone is offered treatment. Thus, to the extent that 
overdiagnosis of cancer occurs, it leads to overtreatment (Brawley, 2017; Independent UK 
Panel on Breast Cancer Screening, 2012) - surgery, radiotherapy and other adjuvant 
therapy – that will not benefit individuals but which may harm them through physical and 
psychological consequences that can impact quality of life and life expectancy (Esserman 
et al, 2014). 
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As for all healthcare interventions, the potential benefit of cancer screening must be 
weighed against the potential harm. An earlier Cochrane review of screening 
mammography for breast cancer quantified the benefit (Gøtzsche & Jørgensen, 2013). The 
authors estimated that breast cancer specific mortality was reduced by approximately 19% 
in randomized trials in which women were invited to screening, if all available trials were 
combined. They noted, however, that there was no significant benefit when the analysis 
was restricted to the best quality trials. In that review, they identified overdiagnosis and 
overtreatment as harms of screening that should be weighed against the benefit but did 
not undertake a meta-analysis to derive a summary estimate of overdiagnosis. 
Although early detection of breast cancer may lead to mortality benefit, overdiagnosis is 
an unintended but inevitable risk of trying to detect pre-symptomatic cancer in age groups 
at significant risk of death from other causes. Thus, if women wish to be screened because 
they value the opportunity to reduce their risk of dying from breast cancer, that inevitably 
entails accepting an addition risk of diagnosis and treatment, including the risk of 
overdiagnosis and overtreatment. If screening catches many slow growing cancers that 
would not cause symptoms or death, then the harms may begin to outweigh the health 
benefits both for populations and for individual women. Therefore establishing the 
frequency of overdiagnosis is critically important to determine whether the net benefit 
justifies the resources required by the program, and to provide the best information 
possible to help healthy women weigh up the potential benefit versus the potential harm 
of participating in breast cancer screening.  
To reliably estimate the effect of screening on breast cancer incidence we look to 
randomised controlled trials. Of the nine large trials undertaken, only three were suitable 
to accurately measure overdiagnosis (Miller et al, 2000; Miller et al, 2002; Zackrisson et al, 
2006). An independent meta-analysis of these trials suggests that the percentage of 
screened women who are diagnosed with breast cancer that experience overdiagnosis is 
19% (Independent UK Panel on Breast Cancer Screening, 2012). The authors of this 
analysis, however, emphasised the uncertainty around this estimate due to the scarcity of 
data, the small number of cases and the fact that all women were not followed to the end 
of their lives. 
Of particular concern is that these three trials were undertaken a long time ago. 
Contemporary screening technology is more sensitive than film, and the incidence of 
ductal carcinoma in situ (DCIS) has increased because of screening (Barchielli et al, 2005; 
Kerlikowske, 2010; Kricker et al, 2004; Sørum et al, 2010; van Steenbergen et al, 2009; Virnig 
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et al, 2010). There are also differences between the screening mammography trials and 
international programs in target age, screening intervals, mammography views, reads and 
follow-up time. An analysis of non-randomised studies would have the advantage of 
evaluating current trends in breast cancer incidence and help quantify overdiagnosis in 
screening programs to better inform individuals, clinical practice and policy. 
More contemporary estimates of overdiagnosis taken from non-randomised studies range 
from 0% up to 54% (Biesheuvel et al, 2007; Nelson et al, 2016) . The variation in these 
results may represent discrepancies in the calculation of the estimates as well as 
methodological differences such as allowance for lead-time, length-time and volunteer 
biases.  
Lead time is the amount of time screening advances the diagnosis of cancer. Lead time 
bias inflates survival statistics when early detection leads to an earlier diagnosis but does 
not extend lifetime. Allowing for lead time is essential in studies of screening because it 
causes a temporary increase in cancer incidence. 
Length time bias (also known as prognostic selection bias (Morrison, 1982) and 
overdiagnosis bias) (Black, 1998), occurs because screening is more likely to detect slow-
growing and non-progressive cancers which have a better prognosis compared to rapidly 
progressing tumours. It is why we might expect screening to detect cancers that are 
overdiagnosed. 
Volunteer bias (a type of selection bias) is where people who choose to participate in 
screening tend to be different compared those who do not. Individual who attend 
screening are generally healthier, have better health behaviours, and their outcomes tend 
to be better because of this (Falk et al, 2013; Puliti et al, 2012b). They may also represent 
the worried well; that is, people who do not have symptoms but are at higher risk of breast 
cancer (Moss et al, 2006). Good quality studies such as randomised controlled trials help 
to avoid these biases, but they are difficult to control for in non-randomised studies.  
Description of the intervention 
Screening mammography involves an x-ray of both breasts (one-view or two-view using 
film or digital mammography) in asymptomatic women to detect a suspicious abnormality 
and classify them at high or low risk of breast cancer. If a woman has an abnormality 
detected she may undergo further investigations such as clinical examination, 
mammography, ultrasound and biopsy procedures. Women who receive a diagnosis of 
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breast cancer are treated with surgery (breast-conserving surgery or mastectomy) and may 
receive radiotherapy and systemic therapies (one or a combination of hormone therapy, 
chemotherapy, HER2 blockade and other biological therapy). 
How the intervention might work 
Screening mammography works via early detection and treatment. Rather than waiting 
for symptoms such as a lump to appear before treating breast cancer, we look for disease 
before these signs develop and thus advance in time the diagnosis. By shifting the 
incidence to an earlier stage, breast cancer should be more curable and require less 
intensive treatment, thereby reducing the incidence of cancers that first present as 
advanced disease (Morrison, 1992). However, International data from non-randomised 
studies demonstrate a significant increase in early-stage disease, with minimal or no 
decline in advanced breast cancer (Autier et al, 2011; Bleyer & Welch, 2012; de Glas et al, 
2014; Jørgensen et al, 2017; Kalager et al, 2012; Lousdal et al, 2014). We are finding that 
cancers behave in a variable way and do not necessarily lead to metastases and death 
(Welch & Black, 2010; Zahl et al, 2008). Thus an unintended consequence of screening is 
the detection of preclinical cancers that are either 1) non-progressive or regressive - that 
is, breast cancers that were never destined to present clinically or cause harm; or 2) breast 
cancers which would have progressed so slowly that women die from other causes before 
symptoms would have appeared.  
Why it is important to do this review 
One of the difficulties in making recommendations about screening mammography is that 
the benefits have been more extensively studied than the harms. Furthermore, the 
absolute benefit to harm ratio may be finely balanced, or may have become less favourable 
as treatments for breast cancer improved (Birnbaum et al, 2016), making it increasingly 
important to carefully quantify the trade-offs in the current context. To help provide an 
overview of the potential mortality benefit versus the potential harm of screening 
mammography, we will discuss the outcomes of our analysis in the context of the existing 
Cochrane Review (Gøtzsche & Jørgensen, 2013). 
For clinicians and patients, overdiagnosis adds complexity to informed decision making. 
Policymakers face the challenge of how best to respond to and mitigate the problem. 
Whereas early detection may help some, it undoubtedly hurts others, and the amount of 
harm can affect women’s choices (Hersch et al, 2015). There is disagreement over the 
precise amount of overdiagnosis caused by screening mammography (Biesheuvel et al, 
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2007; Canadian Task Force on Preventive Health Care, 2011; Independent UK Panel on 
Breast Cancer Screening, 2012; Myers et al, 2015; Nelson et al, 2016; Puliti et al, 2012a). This 
is in part due to different views on the best study design to observe overdiagnosis, methods 
used to calculate overdiagnosis (de Gelder et al, 2011), appropriate adjustment for lead time 
and the importance of DCIS. Future randomised trials of screening mammography for 
women aged 50-69 years are extremely unlikely due to possible ethical opposition and 
issues with adherence. Further, a recent systematic review of methods suggested that well 
conducted ecological and cohort studies are more appropriate for quantifying and 
monitoring overdiagnosis in cancer screening programs (Carter et al, 2015). Therefore a 
detailed and careful assessment of randomised and non-randomised studies is needed to 
form a more precise estimate of overdiagnosis and inform current appraisals of screening 
mammography and guide decisions of consumers, clinicians and policymakers. As both 
the quantity and quality of evidence about overdiagnosis from non-randomised studies is 
steadily increasing, it seems important to prepare a regularly updated systematic review 
including non-randomised studies to provide contemporary estimates of the magnitude 
of overdiagnosis from breast screening. Further, the methodological standards outlined in 
this review may be applicable to other reviews of non-randomised studies on the harms of 
cancer screening programs. 
Objectives 
To assess the effect of screening mammography for breast cancer on overdiagnosis in 
women over age 40 years at average risk of breast cancer. 
Methods 
Criteria for considering studies for this review 
Types of studies 
We will identify and evaluate all primary epidemiological studies that have quantified 
overdiagnosis resulting from screening mammography, and provide estimates of its 
frequency. We will include: 
• randomised controlled trials, including cluster randomised controlled trials, 
• cohort studies, 
• case-control studies, and 
• ecological studies. 
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We will also search for systematic reviews that report new or previously unpublished data. 
Excluded studies: 
• Systematic reviews that only report or combine quantitative estimates of other 
included study types ( randomised trials, cohort studies, case-control studies and 
ecological studies)   that quantified overdiagnosis, 
• Non-systematic reviews, 
• Modelling studies, and 
• Pathological or imaging studies. 
Types of participants 
Women aged 40 years and over during the active screening period and at average 
(population) risk for breast cancer. 
Types of interventions 
Exposure: Any form of screening mammography (one-view, two-views, film, digital) 
Comparator: no screening mammography 
Types of outcome measures 
There are different ways to calculate overdiagnosis and different estimates address 
different questions. We have found the approach of the Independent UK Panel on Breast 
Cancer Screening helpful, and thus we will present several estimates of overdiagnosis 
using the Panel’s definitions. 
Primary outcomes 
The primary outcome will be the probability of overdiagnosis from the perspective of an 
individual woman: the percentage risk of overdiagnosis among all cancers detected in 
women invited to screening. This outcome is the preferred method of the Independent 
UK Panel, Method C (Independent UK Panel on Breast Cancer Screening, 2012). It reflects 
the probability that a breast cancer diagnosed during the active screening period 
represents overdiagnosis. This measure of overdiagnosis is most relevant to individual 
women considering screening mammography and addresses the question: If I choose to 
participate in screening and have a newly diagnosed breast cancer, how likely is it to 
represent overdiagnosis? 
103 
Secondary outcomes 
2. Absolute risk of overdiagnosis 
The probability that a woman will be overdiagnosed if she chooses to participate in 
screening. This measure answers the question: How many women who are invited to 
screening will be overdiagnosed during the active screening period? 
3. Percentage risk of overdiagnosis of screen-detected cancers 
The probability that a screen-detected cancer represents overdiagnosis (Method D) 
(Independent UK Panel on Breast Cancer Screening, 2012)  
4. Long-term percentage risk of overdiagnosis  
The probability that a cancer diagnosed during the screening period and for the remainder 
of a woman’s lifetime in a woman who is invited to screening will be overdiagnosed 
(Method B) (Independent UK Panel on Breast Cancer Screening, 2012) 
5. The effect of screening mammography on the incidence of early and advanced 
breast cancer 
Search methods for identification of studies 
We will use different methods to search for randomised and non-randomised studies.  
When identifying completed and ongoing randomised controlled trials, we will look to the 
reference list of existing systematic reviews on screening mammography for breast cancer 
(Canadian Task Force on Preventive Health Care, 2011; Gøtzsche & Jørgensen, 2013; 
Independent UK Panel on Breast Cancer Screening, 2012; Nelson et al, 2016). 
Electronic searches 
We aim to include a broad range of non-randomised analyses by conducting a 
comprehensive literature search of non-randomised studies using a variety of sources. We 
will search the following databases: 
(a) The Cochrane Breast Cancer Group's (CBCG's) Specialised Register. Details of the 
search strategies used by the Group for the identification of studies and the procedure 
used to code references are outlined in the Group's module 
(http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.h
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tml). Trials with the key words mammography AND screening AND (detect OR diagnosis 
OR over-diagnosis OR over-detection OR incidence) will be extracted and considered for 
inclusion in the review. 
(b) MEDLINE (via OvidSP). See Appendix 1. 
(c) EMBASE (via EMBASE.com). See Appendix 2. 
(d) CENTRAL. See Appendix 3. 
Searching other resources 
(a) Bibliographic searching 
We will try to identify further studies by hand-searching reference lists of relevant 
systematic reviews and all included studies. A copy of the full article for each reference of 
a potentially eligible study will be obtained. Where this is not possible, attempts will be 
made to contact authors to provide additional information. 
(b) Grey searching 
We will search grey literature for reports and conference proceedings in the following 
databases: 
1. COS Conference Papers Index through ProQuest;  
2. Grey Literature Report and Index, The New York Academy of Medicine; 
3. Health Services Research Projects in Progress (HSRProj); 
4. Mednar; 
5. NIH Research Portfolio Online Reporting Tools (RePORTER); 
6. OAlster; 
7. OpenGrey Repository; 
8. Papers First; 
9. ProQuest Dissertations and Theses Global. 
Data collection and analysis 
We will follow the recommended approach for data collection and management 
documented in the Cochrane Handbook for Systematic Reviews (version 5.1.0) (Higgins & 
Green, 2011). 
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Selection of studies 
At least two authors will independently read titles and abstracts of all records retrieved by 
the searches; any uncertainty or disagreement will be resolved by consensus. They will 
retrieve full-text copies of all studies that potentially meet the inclusion criteria based on 
the abstract, and these will be reviewed independently by two authors according to our 
inclusion criteria to determine their eligibility. Studies published as abstracts only will not 
be included. Any disagreements will be discussed and resolved by a third author if an 
agreement cannot be reached. Excluded studies will be recorded in the ‘Characteristics of 
excluded studies’ table. Multiple publications from the same study will be included only 
once. If one of the authors has contributed to a study, that author will not take part in 
reviewing the relevant manuscript or extracting data from the study. There will be no 
language restrictions and where possible articles will be translated. 
Data extraction and management 
Two authors will independently extract data from the included studies and enter this into 
RevMan. A standardised data extraction form will be pilot tested and modified accordingly 
before use. Information collected will include study design, participants, setting, type of 
mammography, interval between screenings; number of screening rounds; duration of 
screening; co-interventions; adherence to screening; number of cancers identified, follow-
up including data sources and time frames, management of lead time, calculation of 
overdiagnosis; sources of funding and other data relevant to the risk of bias assessments. 
Discrepancies will be resolved by consensus or if they cannot agree, a third author. For 
those studies with more than one publication, we will extract data from all publications, 
with the most recent version considered as the primary reference. 
Assessment of risk of bias in included studies 
Two authors will independently assess and judge the risk of bias for each included study. 
Disagreements will be resolved by discussion. Randomised controlled trials identified 
from the searches will be independently assessed for risk of bias using the Cochrane risk 
of bias tool (Higgins & Green, 2011).  We will assess six forms of bias: selection; 
performance; attrition, detection, reporting and other types of bias. Relevant trial 
characteristics will be judged at low or high risk of bias following the guidelines outlined 
in Higgins (2011). If there is insufficient information to permit judgement, the domain will 
be classified as ‘unclear risk’. 
106 
Non-randomised studies will be independently evaluated and judged according to the Risk 
Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool (Sterne et al, 2016). 
We will address the eight bias domains outlined in ROBINS-I, including confounding, 
departures from intended interventions, missing data, selection of participants into the 
study, classification of interventions, measurement of outcomes, selection of the reported 
results and other types of bias. We will use the guidelines in ROBINS-I to classify the risk 
of bias as low, moderate, serious, or critical. If there is insufficient information to permit 
judgement, the domain will be classified as “No information”.  
Potential confounding factors: 
• Age; 
• Geographical location; 
• Socioeconomic factors; 
• Difference in baseline breast cancer incidence trends between groups; 
• Reproductive factors; 
• Hormone Replacement Therapy (HRT); 
• Obesity;  
• Alcohol consumption; 
• Competing mortality risk from causes of death other than breast cancer.  
Other biases 
Two key areas that have been identified with risk of bias specific to studies estimating 
overdiagnosis are: (i) approaches used to obtain an unscreened comparator group and (ii) 
methods used to adjust for lead-time (Biesheuvel et al, 2007). We will assess risk of bias 
for (i) using existing tools as outlined above and for (ii) using our classification outlined 
below. 
Lead time bias 
Studies that do not allow for lead time overestimate overdiagnosis (Duffy et al, 2008; Puliti 
et al, 2012a). The advance in time of cancer diagnosis due to screening (lead time) causes 
a temporary increase in cancer incidence. Once screening stops, the rate of detection of 
cancers in the previously screened group should be less than the unscreened group, 
compensating for the earlier increase in incidence due to lead time. This phenomenon is 
called the “compensatory drop”. Eventually, the cumulative incidence in the two groups 
will increase at the same rate.  Thus, to provide an unbiased estimate of overdiagnosis, 
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there must be an adjustment for the increase in incidence during the active screening 
period. Importantly, as Baker (2014) points out, lead time only relates to cancers that were 
destined to become symptomatic (progressive pre-clinical cancers) (Baker et al, 2014). This 
is because the definition of lead time requires cancer to present clinically due to symptoms 
in the absence of screening. Thus an overdiagnosed cancer does not have a lead time 
(alternatively, we can think of overdiagnosis as having an infinite lead time because it will 
never cause symptoms). 
Methodology for dealing with lead time is diverse and complex, especially in non-
randomised studies (Baker et al, 2014; Duffy et al, 2008; Gøtzsche et al, 2009; Gulati, 2014; 
Puliti et al, 2012a; Ripping et al, 2017; Zahl et al, 2014), but three main methods exist: 
a) Compensatory drop method: long-term follow-up after screening stops to capture 
and allow for the effects of lead time (compensatory drop, also called “excess 
incidence”, which includes cumulative incidence and early vs late stage methods); 
and 
b) Statistical adjustment: using estimates of average lead time (and its distributions) 
from the literature to adjust for lead time; and 
c) Steady state method: Comparison of incidence (total or stage-specific incidence) 
in invited and control populations once screening has been established longer than 
the expected lead time (screening is in a “steady state”). 
The compensatory drop method is the preferred approach and has been used in 
randomised controlled trials (Miller et al, 2014; Zackrisson et al, 2006). Ecological and 
cohort studies of similar groups of screened and unscreened women that include cancers 
diagnosed both during the active screening period and after screening has stopped, also 
allow for lead time as they capture the compensatory drop. Many observational studies, 
however, use alternative methods or simply do not allow for lead time. Statistical 
adjustments may result in biased results because the magnitude of lead time is contested 
(Duffy & Parmar, 2013; Zahl et al, 2014) and the distributions mostly unknown (Carter et 
al, 2015). Estimates of average lead time of breast cancer are between one and three years 
(Duffy et al, 2008; Feinleib & Zelen, 1969; Walter & Day, 1983), though estimates of average 
lead time based on progressive pre-clinical cancers only are shorter, at around 1 year (Zahl 
et al, 2013). Only a small percentage of breast cancer cases have a pre-clinical duration 
longer than five years (Shen & Zelen, 2001; Walter & Day, 1983). While incidence rates in 
screened women seem to return to the expected (control) rates within five years after 
screening stops (Miller et al, 2014; Zahl & Mæhlen, 2012), we need to capture the full 
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distribution of lead time, including the occasional progressive pre-clinical breast cancer 
with a lead time that is long. Lastly, when estimating overdiagnosis, the lead time 
adjustment should reflect individuals time preferences – women are likely to value more 
immediate consequences of overdiagnosis differently to consequences that may occur well 
into the future (known as temporal discounting of future health outcomes) (Drummond 
et al, 2015). Therefore, for both randomised and non-randomised studies, we will classify 
lead time bias as outlined in Table 1. 
Table 1. Judgement of the risk of lead time bias in randomised and non-randomised 
studies that estimate overdiagnosis. 
 
Risk of bias Criteria Justification 
Low Lead time adjustment was based on a 
comparison of cumulative incidence in a 
screened and unscreened population after 
an ideal follow-up time after screening 
stops (≥10 years). 
(Carter et al, 2015) 
Moderate Lead time adjustment was based on a 
comparison of cumulative incidence in a 
screened and unscreened population after 
a sufficient follow-up time after screening 
stops (5-9 years). 
(Biesheuvel et al, 2007; 
Miller et al, 2014; Puliti 
et al, 2011; Shen & Zelen, 
2001; Walter & Day, 
1983; Zahl & Mæhlen, 
2012) 
Serious Lead time adjustment was based on:  
a) a statistical correction using directly 
observed data and a sufficient mean lead 
time; or  
b) a statistical correction from a model 
which explicitly allowed for progressive and 
non-progressive preclinical cancers, and 
competing mortality. 
(Baker et al, 2014; Zahl 
et al, 2013) 
Critical Lead time adjustment was based on: 
a) an insufficient follow-up time after 
screening stops (<5 years); or  
b) using a statistical correction of lead time 
from a model that did not allow for 
progressive and non-progressive cancer, 
and competing mortality; or  
c) no consideration of lead time. 
(Baker et al, 2014; Zahl 
et al, 2013) 
No Information Insufficient information on which to base a 
judgement about the risk of lead time bias. 
 
  
109 
Measures of intervention effect 
For dichotomous outcomes (that is, breast cancer cases detected), extracted data from the 
original studies for both screened and unscreened groups will be used to estimate the 
cumulative incidence of newly diagnosed breast cancer and/or annual incidence of newly 
diagnosed breast cancer and to calculate the percentage risk of overdiagnosis with 95% 
confidence intervals. Any method that attempts to measure the percentage of 
overdiagnosis attributable to screening mammography should use the excess cancers 
allowing for lead time in the numerator of the percentage calculation. 
Primary outcome 
1. Percentage risk of overdiagnosis of all breast cancers detected in women who are 
invited to screening: 
(Cumulative incidence in the screened group – cumulative incidence in the control 
group) / Total number of all breast cancers detected in screened women during the 
active screening period 
We will use a binomial distribution when calculating the variance (Baker et al, 2014; 
Independent UK Panel on Breast Cancer Screening, 2012).  
When conducting a meta-analysis of overdiagnosis it is important that the denominator 
includes screen-detected, interval and clinically detected breast cancers found in women 
who participate in screening. Firstly, the ratio of screen to interval cancer detection 
increases as the time between the screening interval decreases, so excluding interval breast 
cancer provides an estimate of overdiagnosis that is dependent on screening frequency 
and applicable only to one particular program. As different studies use different screening 
intervals, we need to account for this. This issue was identified by the UK Panel and 
underpins their view that this expression of overdiagnosis is the best way to present 
information to women who are considering participation in screening. Secondly, to allow 
for tumour heterogeneity, we must count all outcomes regardless of method of detection. 
Lastly, excluding some cancer cases from the screened group in randomised controlled 
trials may introduce selection bias, because the women who do not attend screening but 
receive a cancer diagnosis may differ with regards to breast cancer risk and detection rates 
compared to those women who do attend screening and receive a breast cancer diagnosis. 
Estimates of overdiagnosis should include DCIS as this abnormality is primarily detected 
by mammography and currently treated as cancer. Including cancers diagnosed after 
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screening ends in the denominator dilutes the estimate of overdiagnosis, makes it 
dependent on the length of follow-up (Carter et al, 2015), and does not reflect the value 
women may place on more immediate outcomes. 
The percentage risk of overdiagnosis, regardless of method, cannot be directly compared 
to estimates of breast cancer mortality benefit such as relative risk. Both estimates must 
be converted to absolute numbers to provide a fair and standardised comparison. 
Secondary outcomes 
2. Absolute risk of overdiagnosis 
(Cumulative incidence in the screened group – cumulative incidence in the control 
group) / Total number of women who are invited to screening 
This will be expressed as a natural frequency for every 1000 women screened. We will use 
a binomial distribution when calculating the variance. 
3. Percentage risk of overdiagnosis of screen-detected breast cancers: 
(Cumulative incidence in the screened group – cumulative incidence in the control 
group) / screen-detected breast cancers 
When calculating the variance of the percentage risk of overdiagnosis as a proportion of 
screen-detected breast cancers, the numerator includes the cumulative number of 
clinically detected cancers in the screened group which are not part of the denominator. 
To allow for the variability in the cumulative number of clinically presenting cancers in 
the screened group, we will compute bootstrap confidence intervals or asymptotic 
variances assuming the variables follow independent Poisson distributions (Baker 2016). 
4. Long-term percentage risk of overdiagnosis: 
(Cumulative incidence in the screened group – cumulative incidence in the control 
group)/ cancers diagnosed over the active screening period and the entire follow-up 
period in screened women. 
We will use a binomial distribution when calculating the variance (Independent UK Panel 
on Breast Cancer Screening, 2012). 
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5. The effect of screening mammography on the incidence of early and advanced 
breast cancer 
a) We will use summary staging to classify cancer into one of four main 
categories: 
DCIS—Abnormal cells are contained in the lining of the breast duct, but 
have not spread to nearby tissue; 
Localised—Cancer that is limited to the organ in which it began (primary 
site) with no evidence of spread; 
Regional—Cancer that has spread beyond the primary site to nearby lymph 
nodes, tissues, or organs; and 
Distant—Cancer that has spread beyond the primary site to distant parts 
of the body. 
 
b) We will calculate:  
Absolute increase in incidence of DCIS and localised breast cancer per 
100,000 women in a screened population; and 
Absolute decrease in regional and distant breast cancer per 100,000 women 
in a screened population. 
 
c) We will use one or more comparator populations: 
Current unscreened populations; 
Historical unscreened populations; or 
Younger and/or older unscreened populations. 
We will also examine trends in incidence rates of early stage (DCIS or localised disease, 
summary stage I/ II) and advanced stage (regional or metastatic/ distant disease, summary 
stage III and IV) breast cancer before and after implementation of screening. 
Unit of analysis issues 
The unit of our analyses will be women diagnosed with breast cancer. We will include 
intervention arms of one-view or two-view film or digital screening mammography. We 
will include cluster randomised controlled trials. If studies that incorporate clustering in 
their design are found, we will contact the authors to obtain cluster specific counts from 
which we will calculate variances adjusted for clustering. If these data are not available for 
some studies we will apply the intraclass correlation coefficients estimated from the 
studies with available data to adjust the variances. If none of the clustered studies have 
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cluster-specific data available then we will conduct sensitivity analyses assuming a range 
of intraclass correlation coefficients. 
Dealing with missing data 
If possible, we will perform intention-to-screen analyses for randomised controlled trials 
by including all randomised women. When necessary we will contact authors of 
publications to ensure the completeness of data. If data remain unavailable, we will try to 
estimate the missing data using the available information. Where data are missing, we will 
assume that participants with missing data did not receive a breast cancer diagnosis. We 
will report the proportion of participants with missing outcome data and consider the 
potential impact of the missing data on the results. 
For non-randomised studies, we will exclude participants with missing data and perform 
a complete-case analysis. We will report the proportion of participants with missing 
outcome data and consider the potential impact of the missing data on the results. 
Assessment of heterogeneity 
We will assess clinical, methodological and statistical heterogeneity. Pre-specified 
subgroup analysis will be conducted to explore possible causes of heterogeneity (see 
‘Subgroup analysis and investigation of heterogeneity’).  Inconsistency across studies will 
be discussed and assessed by visual inspection of the forest plots and, when appropriate, 
calculating the I2 statistic with 95% confidence intervals (Higgins et al, 2003). Given the 
clinical and methodological diversity of non-randomised studies, any meta-analyses will 
be conducted using a random-effects model. We will not perform a meta-analysis if there 
is a very high level of heterogeneity. 
Assessment of reporting biases 
Reporting bias, especially publication bias and outcome reporting bias, will be dealt with 
according to the recommendations of the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins & Green, 2011). We will explore publication bias by producing 
funnel plots and using Egger’s test (Egger et al, 1997). We will visually inspect the funnel 
plot if there are more than ten studies in the meta-analysis. 
Data synthesis 
We will conduct separate meta-analysis (if appropriate) for randomised controlled trials 
and non-randomised studies. If re-analysis of the data provided by randomised controlled 
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trials is required, we will perform intention-to-screen analyses by including all randomised 
women. Analysis by intention-to-screen will underestimate any real effect in women who 
attend screening. Thus as a secondary analysis, we will adjust the primary outcome 
measure for adherence to screening in individual trials using a previously published 
method (Jacklyn 2016). Essentially, this method divides the intention-to-screen effect by 
the proportion attending screening and makes trial results more comparable to non-
randomised study estimates, which often measure the effect in women who attend 
screening. To allow for heterogeneity the DerSimonian and Laird random-effects method 
will be used and 95% confidence intervals presented for both the intention-to-treat and 
adjusted estimates (DerSimonian & Laird, 1986). In case of heterogeneity in the trial results 
(P < 0.10), we will explore possible causes. The intention-to-screen analyses will be 
performed using RevMan 5.3. For the cumulative and deattenuated meta-analyses, we will 
develop a spreadsheet and perform statistical analyses using Microsoft Excel software.  
If clinical heterogeneity is not excessive in the non-randomised studies and pooling results 
is appropriate, then we will conduct a meta-analysis using the DerSimonian and Laird 
random-effects method using RevMan 5.3. To observe changes in screening 
mammography and trends in overdiagnosis, we will also perform a cumulative meta-
analysis (Lau et al, 1992).  Studies will be added one at a time in order of the date of the 
active screening period, and the results summarised as each new study is included. For the 
cumulative meta-analyses, we will develop a spreadsheet and perform statistical analyses 
using Microsoft Excel software. 
If it is possible to combine results from individual studies, we will analyse and present the 
pooled estimates according to study design. We will stratify studies according to risk of 
bias and provide three (stratified) analyses of the intervention effect incorporating: 
1. all studies,  
2. those at low risk of bias, and  
3. those at high risk of bias. 
Forest plots will be drawn to display results across studies according to risk of bias, key 
study design features and date of the active screening period. In the event of important 
heterogeneity, we will not pool data across non-randomized studies and instead provide a 
narrative review and present individual study findings in a summary table according to 
study design. 
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Subgroup analysis and investigation of heterogeneity 
If data are sufficient we will perform subgroup analyses by: 
• Age at intervention (age groups 40 to 49 years, 50 to 69 years, and 70+ years); 
• Study design; 
• Country of study; 
• Date of active screening period; 
• Type of mammography used (one-view, two-view, film, digital); and 
• Frequency of screening (screening interval). 
If heterogeneity is substantial, we will investigate causes by the subgroup analyses and by 
relating the size of effect to the characteristics and risk of bias of the study. Meta-
regression will be considered if there are more than ten studies in the meta-analysis. 
Sensitivity analysis 
If a meta-analyses are feasible, we will assess the impact of heterogeneity on the overall 
pooled effect estimates by removing studies (’outliers’) contributing to heterogeneity. We 
will remove outliers one by one and assess the impact on the overall outcomes. We will 
conduct sensitivity analyses to determine whether findings are sensitive to decisions made 
during the review process such as our assessment of the level of clinical heterogeneity. We 
will evaluate the methods used to handle missing data by excluding these studies in a 
sensitivity analysis, and we will discuss the extent to which the missing data are likely to 
influence the results of the study. 
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Appendix 
Table 2. Excluded study types 
 
Excluded study types Justification 
Systematic reviews that 
report results of other 
studies 
Systematic reviews will be excluded if they merely 
summarise studies that have quantified overdiagnosis (for 
example, by combining data from several estimates of 
overdiagnosis). 
Non-systematic reviews A review of the literature that does not adhere to a 
protocol is subject to substantial biases and limitations 
and therefore insufficient for clinical decision making.  
Modelling studies Modelling studies are useful for addressing research 
questions where direct evidence is difficult to obtain, such 
as with cancer screening, where the data collected or 
duration of follow-up may be limited. Models that aim to 
quantify overdiagnosis may attempt to simulate disease 
progression and outcomes in screened and unscreened 
populations. They are based on data from primary or 
secondary studies and can use multiple other data 
sources, or assumptions to extrapolate beyond the 
observed data. It is challenging to create valid and reliable 
models of cancer screening that estimate overdiagnosis 
due to key uncertainties in the available data, particularly 
with respect to the proportion of preclinical cancers 
which are non-progressive 63. Further, calculation of 
overdiagnosis requires an estimate of the mean duration 
of lead time and the shape of the lead time distribution. 
Because lead time is unobservable in practice, 
assumptions have to be made, without ever being able to 
validate them fully. As the rate of overdiagnosis is implicit 
in the lead time distribution assumptions of the model - 
particularly the tail shape of the lead time distribution 
and non-progressive lesions which have an infinite lead 
time - overdiagnosis cannot be estimated from models. 
For this reason, we will exclude modelling studies from 
our systematic review. 
Pathological or imaging 
studies 
Studies that examine overdiagnosis resulting from non-
progressive disease underestimate total overdiagnosis as 
they cannot account for overdiagnosis due to competing 
mortality. 
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Chapter 8. Discussion and conclusions 
Overview of thesis 
In this thesis I investigated the magnitude of benefits and harms attributable to 
contemporary screening mammography in Australia, with a view to extend this work in 
the future by pooling international estimates of overdiagnosis in a Cochrane Systematic 
Review. Where possible I have presented numeric outcomes using natural frequencies and 
conveyed the uncertainty to facilitate evidence-based decision making for individuals, 
clinicians and policymakers. The questions addressed in the thesis have been identified in 
the screening literature as important targets for empirical investigation and essential to 
monitoring the effects over time of screening programs. My research represents a 
significant step in addressing gaps in the evidence, contributing to the debate about the 
impact that screening mammography has had on stage-specific incidence of breast cancer 
in Australia and the likely consequences of screening for individual Australian women. 
My thesis contains six manuscripts, including four published papers, one resubmission 
under final peer-review and another paper that will be submitted to an international 
journal. Together these add valuable new knowledge to this field. The first paper (chapter 
2) was a meta-analysis that summarised the existing trial evidence for the benefits and 
harms of screening mammography and adjusted pooled estimates of breast cancer 
mortality and overdiagnosis for non-adherence to the trial protocol to evaluate the effect 
of attending screening. Secondly, I applied these deattenuated estimates to a Markov 
model (Chapter 3) and derived screening specific outcomes (recalls for further imaging, 
biopsies, false positives, and interval cancer rates) for the new BreastScreen Australia 
program of biennial screening from age 50 to 74 compared to the previous program of 
screening from age 50 to 69. The next paper (Chapter 4) presented temporal trends in the 
incidence of stage-specific breast cancer in New South Wales before, during and after the 
introduction of screening mammography. I then used this data in Chapter 5 to quantify 
overdiagnosis. In the fifth paper (Chapter 6), I presented trends in the incidence of 
carcinoma in situ of the breast in New South Wales over the past 40 years. Finally, the 
Cochrane Protocol (Chapter 7) outlined methodology for estimating overdiagnosis using 
international estimates from both randomised and non-randomised studies. 
Summary of principal significant findings 
Taken together, my findings suggest that screening mammography reduces the risk of 
death due to breast cancer, but some of the expected benefits have not been realised and 
are consistent with substantial overdiagnosis. 
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My meta-analysis (Chapter 2) found that adjustment for nonadherence to the protocol in 
randomised controlled trials of screening mammography increased the size of the pooled 
mortality benefit and risk of overdiagnosis by up to 50%. By applying these estimates to 
Australian breast cancer incidence and mortality data, I established that the risk of harm 
from screening mammography was greater than the chance of benefit. Further, my results 
showed that extending screening mammography in Australia to older women is likely to 
lead to a less favourable harm to benefit ratio (Chapter 3). When compared with stopping 
at age 69, screening women to age 74 is likely to cause more harm than benefit. I found 
that an additional five years of screening will result in approximately seven more 
overdiagnosed cancers to avert one more breast cancer death.  
The key finding from the analysis of stage-specific breast cancer incidence in New South 
Wales (Chapter 4) is that detection of both early- and late-stage breast cancer has 
increased over the past 40 years, with the greatest rise seen during the established 
screening period for women aged 50 to 69 years. The early detection and treatment of 
DCIS does not appear to be providing benefit by advancing in time the diagnosis of cancers 
that were destined to progress as rates of invasive breast cancer have continued to rise 
(Chapter 6). Further, there has been an additional increase in the detection of DCIS since 
the introduction of digital mammography. The incidence of late-stage breast cancer was 
increasing in women too young to screen, which suggests that some of the increasing 
incidence is due to factors other than screening mammography. After allowing for the 
underlying trend of increasing breast cancer, we found that screening mammography was 
associated with a reduction in the incidence of distant metastatic breast cancers, but this 
was coupled with a substantial increase in the detection of early-stage and regional breast 
cancers. We estimate that around six additional cases of early and regional breast cancer 
are detected for every distant metastatic breast cancer prevented (Chapter 5). 
My study extends previous work in other populations by considering overdiagnosis 
according to stage. I highlight that excess cancer detection is not limited to DCIS; it also 
includes localised and even regional breast cancers. Overall, my results indicate that 
screening mammography provides some benefit, but this needs to be weighed against the 
substantial risk of harm, including false positives and overdiagnosis. My findings raise 
important questions about the value of breast screening and aggressive treatment of in 
situ lesions, especially among older women, and support trials of de-escalated treatment. 
While the estimates of harm presented in my thesis outweigh the numerical benefits, 
choosing whether or not to screen is not a purely utilitarian decision.1 Preferences and 
values affect human willingness to accept harm. The scientific ambiguity in my estimates 
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of benefit and harm are likely to influence people’s perception of risk and decisions,2 and 
there appears to be tolerance of many overdiagnosed breast cancers to prevent one death.3 
Comparison to other studies 
One of the aims of my thesis was to explore a different approach to estimate overdiagnosis 
in Australia to provide comparison with international studies and present a contemporary 
estimate that reflects current screening practice, as well as the duration of the 
BreastScreen program. Three other local estimates of overdiagnosis exist.4-6 The novel 
designs and different methodologies for dealing with lead time in these studies make fair 
comparisons with international estimates of overdiagnosis difficult. Beckmann and 
colleagues (2015) report a nested case-control study based on South Australian data to 
estimate overdiagnosis. They evaluate the impact of one screen on the cumulative 
incidence of breast cancer from 2006 to 2010.6 Thus any estimate of overdiagnosis that 
reflects repeated screening rounds would be inflated compared to their current estimate 
of 13.8% overdiagnosis. Other biases have been described that may have diluted their 
outcome measure.7 Another estimate of overdiagnosis by Beckmann from South Australia 
from 2005 to 2009 used an ecological design and obtained similar results to their case-
control study (12% overdiagnosis). In contrast, we estimated the effect of regular 
participation in screening on overdiagnosis in New South Wales over 25 years – the entire 
“package” of screening, and obtained a much higher estimate (26% to 30%) (Chapter 5). 
Population differences may also explain the disparity in overdiagnosis between South 
Australia and New South Wales. BreastScreen South Australia has the lowest recall rate 
among all Australian programs8 which would reduce opportunities for overdiagnosis. 
Further, South Australia has a substantially smaller population,9 with less ethnic 
diversity and a lower socioeconomic status compared to NSW.10 Morrell (2010) found 
overdiagnosis in NSW to be higher, in the range of 30% to 42%.4 My research into lead 
time (Chapter 7) suggest that their adjustment for lead time was inadequate, and there is 
a serious risk of bias. 
Combined with the existing literature on overdiagnosis, my findings highlight a pattern in 
observational data. Current rates of overdiagnosis approximate 25% to 30%.11-13 My 
estimate is similar to de-attenuated estimates from RCTs (Chapter 2) and the Markov 
model of outcomes for screening mammography (Chapter 3). Further, the benefit to harm 
ratio reported in Chapters 3 and 5 is within the range of estimates from the USA, Canada, 
Europe and the UK where the number of overdiagnosed cancers for every breast cancer 
death averted has been estimated to be as low as 2:1 up to 47:1.14-19 Regardless of the size of 
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the estimate, international studies suggest that screening mammography involves more 
overdiagnosis than benefit. 
Implications and future directions 
Screening mammography and overdiagnosis: the effect of communicating 
risks 
Information on overdiagnosis leads to better informed women.20 Hersch et al. (2013), 
found that an estimate of 30% overdiagnosis (within the range of my ecological study 
results from Chapter 5), surprised women and raised concerns about the best form of 
treatment for screen-detected cancers. Yet this information had little impact on attitudes 
and intentions concerning screening, with many women indicating that they would 
continue to participate in screening.3 
In research outside the scope of this thesis, but related to it, we investigated the impact of 
a decision aid explaining and quantifying overdiagnosis of breast cancer among NSW 
women aged 50 to 69 years on making decisions about participation in breast screening 
(Appendix E).20 The numeric estimates in this decision aid were obtained from the Markov 
model presented in Chapter 3 of my thesis. Using a randomised trial design, we assigned 
participants to either an intervention decision aid (comprising evidence-based 
explanatory and quantitative information on overdiagnosis, breast cancer mortality 
reduction, and false positives) (Appendix E) or a control decision aid (including 
information on breast cancer mortality reduction and false positives). We found that 
information on overdiagnosis increased the number of women making an informed choice 
about breast screening, but these women indicated they were less likely to undergo 
screening.20 
What it means to be overdiagnosed 
My thesis focused on quantifying the risk of harm, as well as the chance of benefit from 
screening mammography. However, the consequences of overdiagnosis are extremely 
important, and I did not measure the downstream effects on women such as disease 
labelling and overtreatment. Overdiagnosis turns otherwise healthy women into patients 
unnecessarily, with the majority undergoing cancer treatment that cannot benefit them. 
The physical adverse effects of breast cancer treatment include pain and scarring,21 
infection,22 cardiovascular morbidity,23 and mortality.24, 25  
127 
Screening mammography has been shown to reduce breast cancer mortality in pooled 
analyses of trials, but it has not been found to significantly reduce all-cause mortality 
despite moderate power in pooled analyses to detect such an effect if it exists.26, 27 This is 
a concern as the consequences of overdiagnosis have the potential to undermine the aims 
of screening: to reduce morbidity and premature death. Overtreatment may cause harm - 
including death due to causes other than breast cancer – through unnecessary treatment 
such as surgery, radiation, chemotherapy and hormone therapy. Although modern surgery 
is very safe, there is the potential for mortality and morbidity from both anaesthesia and 
surgical complications.28, 29 Women who undergo lumpectomy generally have 
radiotherapy to prevent recurrence, the consequences of which includes heart disease,30 
lung cancer,31, 32 agiosarcoma33 and other cancers.34 Our results indicate that overdiagnosis 
includes regional breast cancers, thus the side effects of chemotherapy - such as nausea 
and vomiting, alopecia, and less common risks such as leukaemia35 - could harm some 
women. The use of Herceptin in those with human epidermal growth factor receptor-2 
(HER2) positive breast cancer may introduce another source of cardiotoxicity.36 Long-term 
use of selective oestrogen receptor modulators (SERMs) such as Tamoxifen increase the 
risk of thromboembolism and endometrial cancer.37, 38 Aromatase inhibitors lead to 
increased bone demineralisation and osteoporosis.39, 40 While the individual risks are 
small, given that almost all women undergo surgery and a substantial proportion have 
adjuvant therapy,17, 41 the number of women affected is likely to be substantial. 
Further, psychosocial well-being is adversely affected. The effects of breast cancer 
screening, diagnosis, and treatment on women’s psychological health and quality of life 
have already been extensively researched.42-45 Further work, however, is required to 
uncover how these outcomes may be altered if women are cognisant that they may be 
overdiagnosed and overtreated for a breast cancer which could have been safely left 
undetected. This is a topic for future research. 
Future challenges in quantifying overdiagnosis 
Chapter 7 discussed the variation in reported estimates of overdiagnosis in the literature; 
there are various explanations for this. An ever-present challenge with overdiagnosis is 
eliminating the risk of lead time bias. Because overdiagnosis cannot be observed and thus 
the mean lead time and distributions are largely unknown, statistical methods and 
assumptions are needed to calculate overdiagnosis. This introduces uncertainty, as 
estimates of overdiagnosis are sensitive to these assumptions. Another reason for the wide 
range of estimates of overdiagnosis reported in the literature is random variability. 
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Variability arises in estimates of the lead time distribution and estimates of excess 
cumulative incidence.46 Another source of contention is the choice of denominator. Some 
have called for a consistent estimate of overdiagnosis to be used and reported,47 but 
different estimates have different uses. Rather than aiming for an accurate estimate of 
overdiagnosis due to screening mammography, a more realistic goal is for conclusions 
about the relative magnitude and range with authors reporting a transparent definition of 
the estimate used. 
Preventing overdiagnosis 
My results indicate that screening mammography has resulted in the detection of a 
substantial number of cancers where diagnosis and treatment cannot benefit the woman. 
But as difficult as quantifying overdiagnosis can be, the real challenge is managing it. 
At the heart of overdiagnosis lies the intuitive belief that screening can save lives and faith 
in the certainty of modern medicine - values deeply embedded in our society and culture. 
Therefore, we need to publicly acknowledge that some women might be worse off due to 
screening mammography and educate the community, clinicians, and policymakers about 
the consequences of overdiagnosis. Developing a better understanding of patient and 
societal values regarding overdiagnosis may help with efforts to educate women, so they 
are able to make better informed decisions. 
But tackling overdiagnosis will also require reform to our health care system.48 Screening 
guidelines should be revised to lower the chance of detection of inconsequential cancers 
and the threshold for classification of women with low-risk abnormalities on 
mammograms increased. Calls have been made to use new terminology for carcinoma in 
situ of the breast.49 There is an opportunity in Australia to increase the time between 
mammograms from two to three years, in line with population screening mammography 
programs in the UK. Reducing the frequency of screening would decrease the number of 
false positive biopsies and potentially overdiagnosed cancer, without significantly 
adversely affecting breast cancer mortality rates.17 This would, in turn, improve the harm 
to benefit ratio. Further, risk-based screening could be developed and recommendations 
of infrequent or no screening made based on individual risk. Key performance indicators 
within BreastScreen Australia could also be changed from increasing the participation rate 
to improving informed decision making. 
Less aggressive treatment may reduce some of the harm associated with overtreatment. 
As mentioned in previous chapters, several studies are looking into de-escalation of 
treatment for DCIS. Around one-third of screen-detected invasive breast cancers, 
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however, have good prognosis based on molecular profiling,50 which presents further 
opportunity for less aggressive treatment. 
More rigorous evaluation of new technology and existing policy needs to occur before 
changes are made.51 It is important that randomised controlled trials are used to evaluate 
the effects of new tests with increasing sensitivity, such as tomosynthesis,52 and estimate 
long-term harms and benefits before implementation (Appendix F).53 Further, the 
detrimental effects of extending screening to women in their 70s demonstrated in Chapter 
3 could have been avoided if the Australian Government conducted an independent 
evaluation before announcing the policy change. 
Lastly, health care professionals need to be better educated about overdiagnosis and the 
potential harms of overtreatment, so they avoid pushing women towards screening and 
instead embrace shared decision making. 
Future research 
There is scope for further development and evaluation of aspects of BreastScreen Australia. 
My results suggest extending screening mammography in Australia to older women results 
in a less favourable harm to benefit ratio than stopping at age 69, but I rely on modelled 
estimates of outcomes. Long-term results of the UK cluster-randomised trial of extending 
the NHS breast screening age range may shed further light on the effects of screening 
women older than age 70.54 Future research should prioritise comparative effectiveness 
trials of alternative screening strategies. 
Use of digital mammography has increased over the past decade, and detection rates of 
DCIS continue to rise despite relatively stable screening participation. These findings 
make us question the value of diagnosing such lesions. More data, however, is needed to 
assess the impact digital mammography has on outcomes of BreastScreen Australia and 
rates of overdiagnosis. While we wait to see the outcomes of trials evaluating the effect of 
de-escalated treatment for DCIS, research should focus on the value of performing 
biopsies for carcinoma in situ of the breast. Further, developing biomarkers or other 
strategies to distinguish aggressive forms of these lesions from nonaggressive or indolent 
tumours is a clinical and public health priority. 
The observed temporal increases in incidence rates for breast cancers diagnosed at a 
regional stage that includes women both within and outside of the target screening age 
groups is surprising, and we have been unable to find a definitive explanation for this. 
While stage migration is one likely cause of the recent increase in all women, changing 
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prevalence of risk factors such as HRT and postmenopausal obesity cannot explain the 
increase in younger women. The trend toward increasing age at first full-term pregnancy 
among women may have resulted in increasing numbers of pregnancy-associated breast 
cancers that tend to present at a late stage at diagnosis. Additional studies are needed to 
provide clues as to why the incidence of regional breast cancers has risen over time without 
a commensurate increase in mortality. 
Lastly, a detailed and careful assessment of randomised and non-randomised studies is 
needed to make conclusions about the relative magnitude and range of overdiagnosis and 
inform future appraisals of screening mammography. I will address this gap in knowledge 
through my Cochrane Systematic Review on overdiagnosis due to screening 
mammography. 
Conclusions 
When I started this research project, there was growing evidence that screening 
mammography led to overdiagnosis and a realisation that the benefits and harms are finely 
balanced. This led to questioning of the value of breast screening internationally and 
debate about the trade-offs. Yet evidence was lacking regarding the effect of extending 
invitations to older women and the effect of screening on the stage-specific incidence of 
breast cancer in Australia. 
The research presented in this thesis has demonstrated that in Australia the numerical 
benefits and harms do not appear to be finely balanced. While screening mammography 
can benefit women, it causes net harm. Of critical importance is the finding that screening 
has not decreased the overall incidence of late-stage breast cancer and overdiagnosis 
includes regional breast cancers. Given the substantial financial and emotional investment 
in BreastScreen Australia, it is vital to maximise the benefits of the current program and 
minimise harms. My research suggests that it is time to rethink our current strategies so 
we can shift the balance to net benefit.  
Using existing registry data to describe the effects of screening mammography in Australia 
is useful for identifying gaps in knowledge and guiding future research. Researchers and 
clinicians should not be afraid to communicate to the public the uncertainty surrounding 
the magnitude of overdiagnosis. In fact, failure of screening programs to acknowledge the 
uncertainty surrounding the benefits and harms of screening mammography has 
contributed to overconfidence in screening as a tool to “save lives”. Women, clinicians, 
policymakers, and the wider public need a better understanding of the limitations of 
screening.   
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Appendix B. Supplementary material for Chapter 2 
Appendix 1. Deattenuated prevented fraction 
Glasziou (1992) described a fixed-effect procedure to combine the study specific 
deattenuated estimates for each study (denoted by i) to compute a summary estimate 
(DPF*) of the deattenuated Intervention of treatment effect using inverse-variance 
weighting as follows:  
 
where  =  =  
Since 0 ≤ ∆i ≤ 1, studies with poor adherence will be down weighted relative to studies 
with good adherence in terms of their contribution to the overall estimate. If ∆i=0 for an 
individual trial, then that study would be excluded (e.g. if no one received the 
intervention in either arm, or if, in both arms, 50% received the intervention). 
With large sample sizes we can assume ∆ is a constant. Thus the 95% confidence interval 
(CI) for the study specific deattenuated prevented fraction (DPFi) is estimated by:  
 
where the variance (DPFi) is approximated by: 
( )2 ( ) 
see Glasziou 1 for a more detailed explanation. 
An alternate method for calculating 95% confidence intervals for the DPF at the 
individual study level uses the log transformation of incidence density ratio (IDRi) where 
IDRi = 1 – PF. Since DPFi = PF/∆ = (1-IDRi)/∆, then the 95% CI for ln(IDRi/∆) can be 
calculated and we use 1/∆ -exp(lower CI ln IDRi) and 1/∆ - exp(upper CI ln IDRi)  to 
compute the interval for DPFi. This is the method used in this paper. 
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Appendix 2. Deattenuated estimate for percentage risk of overdiagnosis 
If α is a constant and χ is a random variable and we assume: 
1. approximate normality of a sampling distribution for large n; and 
2. that ∆ is a constant; 
then, to calculate the variance for the deattenuated random variable, χ: 
 
var  
Appendix 3. Deattenuated estimates of percentage risk of overdiagnosis 
with estimates of variance and 95% CIs 
    Malmö I (55-69) Canada I (40-49) Canada II (50-59) 
OD 
 
18.7% 22.7% 16.0% 
VAR(OD) 
 
0.00035 0.00049 0.00032 
∆ 
 
0.47 0.74 0.83 
ODd 
 
40.0% 30.9% 19.2% 
95% CI 
lower bound 32.2% 25.0% 15.0% 
upper bound 47.8% 36.7% 23.4% 
VAR(ODd)   0.00158 0.00090 0.00046 
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Appendix C. Supplementary material for Chapter 3 
Appendix 1. Estimates of expected breast cancer incidence in 2014 for 
unscreened women by 5-year age groups (per 100,000) 
Age group 
(years) 
Expected 
incidence (per 
100,000) 
50-54 185 
55-59 202 
60-64 232 
65-69 247 
70-74 262 
 
Appendix 2. Calculation of breast cancer (BrCa) mortality 
1. Total BrCa mortality(unscreened + screened)  = (proportion of populationunscreened x BrCa 
mortalityunscreened) + (proportion of populationscreened x BrCa mortalityscreened ) 
 
2. Total BrCa mortality(unscreened + screened)  = (proportion of populationunscreened x BrCa 
mortalityunscreened) + (proportion of populationscreened x (RR of BrCa mortalityscreened 
x BrCa mortalityunscreened)) 
 
Rearranging this formula gives: 
 
3. Breast cancer mortalityscreened = (RR x Total BrCa mortality (unscreened + screened)) / 
(proportion of populationunscreened + RR x proportion of populationscreened) 
 
Note: 
RR = Relative risk of BrCa mortalityscreened 
 
 
1. Glasziou P. Meta-analysis adjusting for compliance: the example of screening for 
breast cancer. J Clin Epidemiol. 1992;45(11):1251-1256. 
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Appendix 3. Cumulative outcomes for women who undergo screening over 20 years (original programme) or 25 years 
(current programme) and those who do not  
Figures are for 1000 women who begin screening at age 50 years. Outcomes are cumulated until age 74 for incidence and age 79 for mortality 
for both screening programs. 
 
Original program Current program Current 
program vs 
original 
program 
 
Target age 50-69 years Target age 50-74 years 
 
Begin screening at age 50, 10 
biennial screens over 20 years 
Begin screening at age 
50, 13 biennial screens 
over 25 years 
 
  Screening 
No 
screening Screening 
No 
screening 
Difference 
in 
outcomes 
in 
screened 
women  
Cumulative number of women who:           
Procedures 
     
Are recalled for more tests 443.6 
 
545.5 
 
101.9 
Undergo: 
     
Extra imaging (mammography and/or ultrasound) or clinical 
examination only 293.2 
 
351.9 
 
58.7 
Biopsy (total with at least 1 biopsy) 150.4 
 
193.6 
 
43.2 
Fine needle aspiration biopsy 29.7 
 
40.2 
 
10.5 
Core biopsy 83.8 
 
103.7 
 
19.8 
Open biopsy 36.9   49.7   12.9 
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Receive a false positive result 386.4   464.5   78.0 
Breast cancer cases (summed to age 74) 
Receive a diagnosis of invasive breast cancer at screening 45.1 
 
65.0 
 
19.9 
Develop an interval cancer 17.7 
 
21.6 
 
3.9 
Receive a diagnosis of DCIS* 12.0 0.7 16.0 0.7 4.0 
Totals: 
     
Receive a diagnosis of breast cancer at screening 57.1 
 
81.0 
 
23.9 
Receive a diagnosis of invasive breast cancer 73.9 52.2 86.5 52.2 12.6 
Receive a breast cancer diagnosis of any kind (invasive, DCIS or 
interval) 85.9 52.9 102.6 52.9 16.6 
Receive a diagnosis of breast cancer at screening that is 
overdiagnosed and overtreated 22.1   30.4   8.3 
Mortality (summed to age 79) 
Die from breast cancer 14.8 18.6 13.7 18.6 -1.1 
Die from causes other than breast cancer 213.2 212.5 213.2 212.4 0.0 
Die from all causes 227.9 231.1 226.9 231.1 -1.1 
Avoid dying from breast cancer 3.8   5.0   1.2 
Harm to benefit ratio 
     
Overdiagnosed cases per breast cancer death averted 5.8   6.1   0.3 
Overdiagnosed cases per breast cancer death averted (marginal 
effect of an extra five years of screening) . 
 
. 
 
7.0 
*Diagnostic procedures reflect the number of times the procedure was performed per 1000 women         
†Ductal carcinoma in situ, presenting clinically with symptoms and detected at screening  
Due to rounding, some totals may not correspond with the difference of the separate figures.  
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Appendix D. Letter of support for Chapter 7 from the Cochrane 
Collaboration 
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Appendix E. Additional publication 1 
This publication used the outcomes from Chapter 3 in a decision aid on screening 
mammography for breast cancer. The publication is relevant to this thesis but does not 
form part of it. 
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Appendix F. Additional publication 2 
This publication is relevant to this thesis but does not form part of it. 
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